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BK polyomavirus (BKPyV) is a small DNA icosahedral virus measuring about 45nm in 
diameter, and it was first isolated in 1971. BKPyV infection is ubiquitous and usually 
asymptomatic; however, BKPyV reactivates in immunosuppressed transplant patients and causes 
two diseases, polyomavirus associated nephropathy (PVAN) and hemorrhagic cystitis (HC). Due 
to a lack of specific antiviral drugs, the first-line treatment for BKPyV reactivation is to reduce 
immunosuppression in PVAN patient or to target host DNA synthesis machinery in HC patient. 
None of the current treatments is optimal; therefore, elucidating details of the BKPyV life cycle 
will potentially benefit therapy development and uncover interesting viral and cell biology. 
Despite being isolated more than 40 year ago, details of the BKPyV life cycle require 
further elucidation. BKPyV has been considered to infect host cells via a caveolin-mediated 
pathway. In order to study viral entry in greater detail, caveolin 1, caveolin 2, and clathrin heavy 
chain were silenced with siRNA in renal proximal tubule epithelial (RPTE) cells. Our 
experiments showed that caveolin 1, caveolin 2, and clathrin heavy chain knockdown did not 
block BKPyV infection. However, knocking down UDP-glucose ceramide glucosyltransferase 
(UGCG), an enzyme required for ganglioside synthesis, decreased BKPyV infection. This 
suggests that there is a caveolin- and clathrin-independent pathway during BKPyV entry in 




To further identify host factors associated with BKPyV entry and intracellular trafficking, 
a whole genome siRNA screen was performed on BKPyV in RPTE cells. The DnaJ heat shock 
protein family, which has previously been implicated in BKPyV entry, was our top hit. The other 
hits we identified have not been previously reported; however, many of them are involved in 
vesicular transport. After validating our top interesting hits, a protein complex was identified to 
be essential for BKPyV infection. Considering that all of these proteins localize to the ER 
membrane and participate in the Golgi to ER trafficking, the Golgi to ER trafficking pathway 








Polyomaviruses are a group of non-enveloped icosahedral DNA viruses about 45 nm in 
diameter. Initially, both polyomaviruses and papillomaviruses were classified as two genera in 
the Papovaviridae family 1. Eventually in 2001 the family was divided into Polyomaviridae and 
Papillomaviridae 2. The first member of the Polyomaviridae family is murine polyomavirus 
(MPyV), which was identified as a filterable agent that causes salivary gland carcinomas in mice, 
and it was named with the Greek roots of multiple (poly-) tumors (-oma) 3. Polyomaviruses have 
a broad range of host tropism, having been demonstrated as mainly capable of infecting 
mammals and birds. After the discovery of the first two human polyomaviruses BKPyV 4 and 
JCPyV 5, an additional 11 human polyomaviruses were identified with the help of sequencing 
techniques, including KIPyV 6, WUPyV 7, MCPyV 8, HPyV6, HPyV7 9, TSPyV 10, HPyV9 11, 
HPyV10 12, MWPyV 13, MXPyV 14 and STLPyV 15. Although polyomaviruses have 
demonstrated their abilities to induce tumors in mice, a majority of polyomaviruses do not 
directly cause human cancer. MCPyV is the only polyomavirus that causes a human cancer, 




with various human diseases 16, while more research is required in order to reveal the links 
between other polyomaviruses and human diseases. 
BK Polyomavirus 
BK Polyomavirus (BKPyV) was first isolated from a kidney transplant patient (with the 
initials B.K) who was hospitalized for ureteric obstruction in 1971 4. Subsequent serology studies 
revealed a crucial fact, that BKPyV infection is ubiquitous regardless of geographic location, 
with over 80% of adults worldwide testing seropositive 17. Seroconversion for BKPyV usually 
occurs during early childhood 18, and the transmission route of BKPyV is not yet fully 
understood. It has been speculated that BKPyV is transmitted via a respiratory route, based on 
sporadic reports that BKPyV can be detected from the respiratory tract 19-21. After the initial 
exposure, BKPyV establishes a persistent infection in uroepithelium cells, with periodic urinary 
shedding of viruses. Despite the fact that BKPyV infection is ubiquitous, BKPyV rarely causes 
any symptoms in most immunocompetent individuals, even though BKPyV can be periodically 
detected in the urine. However, in immunosuppressed patients, BKPyV occasionally reactivates 
and directly causes two major human diseases: polyomavirus associated nephropathy (PVAN) 
and hemorrhagic cystitis (HC) 22. PVAN is one of the major causes of graft failure after kidney 
transplant. Up to 10% of renal transplant recipients suffer from PVAN, and up to 80% of PVAN 
patients experience allograft loss 23. In a recent study, 16.6% of the allogeneic hematopoietic cell 
transplant patients suffered from HC, and BKPyV viruria was detected in 90% of the HC patients 
24. Taking into account that roughly 70,000 kidney and 50,000 bone marrow transplants occur 
annually according to WHO reports, and that the only treatment is to reduce immunosuppression 




cycle of BKPyV and establishing a detailed virus infection model will undeniably benefit future 
research and help to reveal potential drug targets.  
Similar to the other polyomaviruses, BKPyV is a small virus with a relatively simple 
structure. The BKPyV capsid is composed of three capsid proteins: the major capsid protein VP1 
and two minor capsid proteins, VP2 and VP3. Based on studies of the other polyomaviruses, 360 
copies of the VP1 protein first form 72 pentamers with intrapentameric disulfide bonds 25,26. 
Each VP1 pentamer binds one copy of one of the minor capsid proteins. The minor capsid 
proteins are buried in the center of the pentamers and anchored by hydrophobic interactions 25,27. 
The 72 subunits finally assemble into the shell of BKPyV in a T=7 manner with interpentameric 
disulfide bonds and calcium interactions 28-30.  
Inside the capsid of BKPyV, a 5.2 kb double stranded circular DNA genome is associated 
with host histones in the same way as SV40 31, and the DNA forms a pearl necklace-like 
structure called a minichromosome 32,33. The circular DNA genome can be arbitrarily divided 
into three regions (Figure 1.1): early, late, and non-coding control region (NCCR). The early 
region encodes three proteins, including large tumor antigen (TAg), small tumor antigen (tAg), 
and truncated tumor antigen (truncTAg) 34. The late region encodes all the capsid proteins and 
agnoprotein. The NCCR is equipped with all the necessary promoters for viral transcription. 
Recombination in the NCCR is fairly common between BKPyV strains. 
Other than capsid proteins, BKPyV only encodes another four viral proteins. TAg is one 
of the most studied viral proteins. TAg functions as a helicase/ATPase that binds to the 
replication origin located in the NCCR in the form of hexamers and initiates viral genome 
replication. In addition, TAg also interacts with and inactivates tumor suppressors p53 35 and 





Figure 1.1: A schematic view of the genome of BKPyV. 
The double stranded circular DNA genome of BKPyV can be arbitrarily divided into three 
regions: early (Green), late (Red), and non-coding control region (NCCR, Orange). Protein 






cell proliferation 37. Compared to TAg, the function of tAg is much less clear, and most 
polyomavirus tAg studies were performed on SV40 38. Owing to the similarities between SV40 
and BKPyV, BKPyV tAg is predicted to promote S phase entry by interacting with PP2A via a 
CxxxPxC motif 39. In addition to TAg and tAg, our lab also discovered a truncated form of TAg 
expressed from an alternatively spliced mRNA 34. The function of this protein has not yet been 
determined. The agnoprotein regulates viral egress by interacting with α-SNAP, and 
agnoprotein-deficient BKPyV mutant is about 50% less infective compared to wild type virus 
40,41. More studies are necessary to further reveal the detailed functions of tAg, truncTAg, and 
agnoprotein.  
Current model of entry and intracellular trafficking 
Polyomaviruses bind to various gangliosides, and some of the polyomaviruses take 
advantage of gangliosides as receptors 42: SV40 attaches to ganglioside receptor GM1 43; MPyV 
binds ganglioside receptors GD1a and GT1b 44; virus-like particles of JCPyV bind gangliosides 
GM3, GD2, GD3, GD1b, GT1b, and GQ1b 45; TSPyV binds to GM1 46; and BKPyV binds to its 
ganglioside receptors GT1b and GD1b (Figure 1.2A) 47. The pentameric VP1 structures of many 
polyomaviruses have been solved, including SV40 29,48, MPyV 49, JCPyV 50, MCPyV 51, KIPyV 
and WUPyV 52, LPyV 53, HPyV6 and HPyV7 54. Based on the capsid structure analysis, HPyV9, 
BKPyV, SV40, MCPyV, LPyV, JCPyV, and MPyV are predicted to interact with sialic acids 
with similar binding pockets located between two VP1 monomers 46. On the other hand, the 
canonical sialic acid interacting pockets of HPyV6 and 7 are obstructed from interacting with 
sialic acid 54, indicating that polyomaviruses may also use receptors other than gangliosides. 




angstroms away from the canonical pocket 46; therefore, HPyV6 and HPyV7 may also interact 
with sialic acid with a novel pocket similar to the majority of polyomaviruses.  
Whether polyomaviruses require co-receptors is still unclear. Several glycoproteins have 
been reported as co-receptors, however, the functions of these glycoproteins with respect to 
infection are still controversial. Major histocompatibility complex I was initially considered as a 
receptor for SV40 55, but subsequent experiments rebutted this idea 56,57. Moreover, integrin was 
identified as a co-receptor for MPyV 58, and it also coordinates endocytic signal transduction for 
SV40 59. In addition, JCPyV relies on the glycosylated serotonin receptor 5TH2A to establish 
efficient infection 60. On the other hand, digesting membrane proteins with proteinase K did not 
block MPyV infection; on the contrary, proteinase K treatment increased MPyV infection. 
Moreover, MPyV enters non-productive pathway without proper ganglioside receptors 61. Both 
of these experiments suggest that glycoproteins serve as traps instead of co-receptors for 
polyomavirus. More studies are required to reveal the real function of glycoproteins during 
polyomavirus infection. 
After initial attachment, different polyomaviruses have been reported to follow different 
endocytic pathways. SV40, MPyV, and BKPyV have been considered to use a caveolin-
mediated pathway for internalization 55,62,63. However, subsequent experiments showed that 
SV40 and MPyV infect cells via a caveolin- and clathrin-independent pathway 64-66. In addition, 
JCPyV was considered to use the clathrin-mediated pathway for infection 67. Upon endocytosis, 
particles were found immobilized in plasma membrane invaginations 63,64,66. Several experiments 
showed that cell signaling may also play a role during viral endocytosis: a tyrosine kinase 
inhibitor, genistein, blocks polyomaviruses infection 43,64,68; SV40 activates AKT via PI3K 59; 




important for many endocytic processes; however, disassembly of actin filaments does not 
impact the endocytic process of MPyV or BKPyV 70,71, suggesting that actin filaments  
are dispensable for vesicle formation. Dynamin proteins are important for the scission of newly 
formed vesicles from the cell membrane during caveolin- and clathrin-dependent endocytosis 72; 
however, expressing dominant negative dynamin does not block MPyV infection 73,74; therefore, 
the fission step of polyomavirus entry is still not understood. 
Internalized polyomaviruses are packaged in tight-fitting vesicles 64,75-77, and then they 
enter the endosome (Figure 1.2B) 66,78-80. It has been reported that there is an intermediate 
compartment called the caveosome before polyomavirus enters the ER 81,82; however, subsequent 
studies demonstrate that the caveosome is more likely to be an artifact. The acidification of the 
endosome is essential for polyomaviruses infection 66,80,83. Acidification and maturation of late 
endosome/lysosome activate a ganglioside sorting machinery that involves Rab 5, Rab 7, Rab 9, 
and Rab 11 proteins 66,80,84. After sorting through the late endosome/lysosome, vesicles that 
contains polyomaviruses traffic along microtubules and fuse to the ER at 8-12 hours post 
infection (Figure 1.2C) 71,83,85,86. 
ER lumen proteins are important for polyomavirus disassembly and egress from the ER 
(Figure 1.2D) 83,87-89. Protein disulfide isomerases induce capsid conformational changes and 
minor capsid protein exposure 62,83,90-94. These exposed minor proteins insert into the ER 
membrane 95,96, and partially disassembled polyomaviruses penetrate the ER membrane and enter 
cytosol through the endoplasmic reticulum associated degradation (ERAD) pathway 87,88,97-99. In 
the cytosol, the nuclear localization signal of minor capsid protein guides polyomaviruses into 






Figure 1.2: The current model of BKPyV entry and intracellular trafficking. 
(A) BKPyV attaches to its receptor, ganglioside GD1b or GT1b, on the cell membrane and gets 
internalized by a caveolin-mediated endocytosis pathway. (B) Internalized BKPyV traffics to the 
endosome. (C) BKPyV traffics to the ER along microtubules after the acidification of the 
endosome. (D) BKPyV partially disassembles in the ER and translocates into the cytosol. (E) 






RNA interference screening 
BKPyV does not encode any DNA polymerase; thus the host DNA replication machinery 
is indispensable for viral replication 103,104. In order to fully access the DNA replication 
machinery, BKPyV must traffic from outside the host cell and deliver its viral genome to the cell 
nucleus. Because of the nature of BKPyV replication, the most practical strategy to block viral 
infection would be to block the pathways that BKPyV uses during entry. Therefore, elucidating 
the trafficking pathway that BKPyV undergoes is not only important for understanding viral 
biology but also potentially important for identifying drug targets. 
Our laboratory has demonstrated that the polyomavirus SV40 traffics differently in 
monkey kidney CV-1 cells than it does in primary human renal proximal tubule epithelial 
(RPTE) cells, which are the natural host cells for BKPyV replication 97. Because much of the 
current model of BKPyV entry and trafficking is built on research using African green monkey 
kidney cells, our findings with SV40 drew our attention to the possibility that BKPyV may 
traffic differently in RPTE cells. To determine whether more such differences exist, in chapter 2, 
I re-examined the BKPyV entry process in RPTE cells. Interestingly, BKPyV did not follow the 
same entry pathway as it does in monkey cells 105. Our results show that BKPyV entry is 
dependent on gangliosides (GT1b/GD1b), but independent of caveolin and clathrin. Moreover, 
most of the details of BKPyV trafficking are not yet revealed in the current models, nor have 
host factors assisting BKPyV infection been identified. In order to identify more host factors 
associated with BKPyV infection and to enrich the details of the BKPyV life cycle model, in 
chapter 3, I performed a whole genome siRNA screen on BKPyV. 
Numerous assays have been developed for identifying host factors associated with viral 




screen. RNA interference (RNAi) is a post transcriptional regulation mechanism that is generally 
conserved in eukaryotic cells 106. It was first reported in plant cells in 1986 107. RNAi had not 
been applied to biological research until 1998 when siRNA, a short (~22-nucleotide) double 
stranded RNA, was introduced as a tool 108. Barely two years after the introduction of siRNA 
methods, genomic siRNA screens were performed in C. elegans 109. After the completion of the 
human genome project in 2006, whole genome siRNA screening in human cells became 
possible. Silencing every human gene with an siRNA library and assessing the effects of the 
knockdown on BKPyV infection allows the dissection of the functions of individual host 
proteins during the viral life cycle. siRNA screens have been extensively applied to viral studies, 
such as HIV 110, West Nile virus 111, HPV 112, VSV 113, and another polyomavirus, SV40 114 , and 
hundreds of host factors associated with these virus have been identified. However, no genome-
wide siRNA screening has been reported for BKPyV. 
Due to our previous finding that polyomavirus infection is cell type- and species-specific 
97, we wished to identify host factors in the natural host cells of BKPyV, human primary RPTE 
cells. Existing strategies for siRNA screens could not be directly adapted to the study of BKPyV 
study. Therefore, a novel strategy based on cell cycle arrest was developed, and a whole genome 
siRNA screen was performed on BKPyV in RPTE cells. With the help of whole genome siRNA 
screening, we identified a series of potential host factors that may be involved in BKPyV 
infection. By further validating our primary results, we found that the off-target effect of siRNA 
severely limited the efficiency of the siRNA screen. After validating our primary screen results, 
we identified RAB18, STX18, and the NRZ complex as our top hits, which may work together in 
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Caveolin- and clathrin-independent entry of BKPyV into primary human 
proximal tubule epithelial cells
Abstract 
BK polyomavirus (BKPyV) is a human pathogen that causes polyomavirus-associated 
nephropathy and hemorrhagic cystitis in transplant patients. Gangliosides and caveolin proteins 
have previously been reported to be required for BKPyV infection in animal cell models. Recent 
studies from our laboratory and others, however, have indicated that the identity of the cells used 
for infection studies can greatly influence the behavior of the virus. We therefore wished to re-
examine BKPyV entry in a physiologically relevant primary cell culture model, human renal 
proximal tubule epithelial cells. Using siRNA knockdowns, we interfered with expression of 
UDP-glucose ceramide glucosyltransferase (UGCG), and the endocytic vesicle coat proteins 
caveolin 1, caveolin 2, and clathrin heavy chain. The results demonstrate that while BKPyV does 
require gangliosides for efficient infection, it can enter its natural host cells via a caveolin- and 
clathrin-independent pathway. The results emphasize the importance of studying viruses in a 





BK polyomavirus (BKPyV) was initially isolated in 1971. Since then, the study of the 
BKPyV life cycle has been ongoing for more than 40 years. The polyomaviruses utilize both 
productive and non-productive pathways to be internalized 1; therefore, morphological 
colocalization observations can be deceiving and inconsistent with functional studies. The first 
isolated polyomavirus, murine polyomavirus (MPyV), has been considered to infect host cells 
via a caveolin-mediated endocytic pathway 2. However, subsequent experiments showed that 
MPyV could infect caveolin-deficient cell lines 3,4. In addition, SV40, similar to the MPyV, was 
also reported to rely on caveolin proteins for viral entry 5; however, SV40 is not only able to 
establish a successful infection in caveolin knockout cells, but is also capable of infecting 
caveolin knockout cells with additional clathrin knockdown 6. Considering that the capsid genes 
of polyomavirus are partially conserved and the capsid structures of polyomaviruses are similar 
7, all the previous findings prompt the possibility that BKPyV entry could be independent of 
caveolin and clathrin. 
The current model for the BKPyV life cycle begins with viral attachment to the cell 
surface via an interaction between the major capsid protein VP1 and the BKPyV receptors, b-
series gangliosides (GD1b/GT1b) 8,9. Specific co-receptors for BKPyV have not been identified, 
but data suggest that an N-linked glycoprotein with (2,3)-linked sialic acid may function as a co-
receptor 10. Caveolin-dependent endocytosis has been previously implicated in BKPyV entry into 
host cells, and gangliosides are commonly enriched within lipid rafts where caveolin-dependent 
endocytosis frequently takes place 11. After initial attachment to receptors, viral particles enter 
caveolin-coated plasma membrane invaginations named caveolae. The caveolae coat protein, 




internalized individual BKPyV particles have been detected in tight-fitting vesicles 6,14. 
Disturbing caveolin-dependent endocytosis through removal of cholesterol from the plasma 
membrane or through transfecting a dominant negative caveolin 1 mutant into cells significantly 
inhibited BKPyV infection 12,13, while disturbing actin polymerization did not affect the BKPyV 
endocytic process 15. After internalization, it is believed that BKPyV-containing vesicles fuse 
with the endosome in the same way as other polyomaviruses 4,16,17. Our laboratory demonstrated 
that acidification of the late endosome/lysosome is essential for infection 18. BKPyV then traffics 
to the ER along microtubules 18,19. After trafficking to the ER, the BKPyV capsid partially 
disassembles in the ER lumen, egresses from the ER via the endoplasmic reticulum associated 
protein degradation (ERAD) pathway, and enters the cytosol before it translocates into the 
nucleus using the importin α/β pathway 20,21.  
Electron microscopic images of cells infected with BKPyV revealed that BKPyV 
particles were individually encapsulated in tight fitting vesicles after endocytosis 6,14. Caveolin- 
and clathrin-dependent endocytic pathways are two major and well-studied pathways that form 
small endocytic vesicles 22. Additionally, there are several caveolae- and clathrin-independent 
pathways that generate similar vesicles. Caveolin proteins are a family of cholesterol binding 
proteins comprised of three members 23, caveolin 1, caveolin 2, and caveolin 3. Caveolin 1 and 
caveolin 2 are ubiquitously expressed in cells including epithelial cells, while caveolin 3 is 
specifically expressed in muscle cells. Caveolin proteins were named because they all serve as 
caveolae coat proteins 24; however, only caveolin 1 has been demonstrated to be required for 
caveolae formation, since caveolae formation is absent in caveolin 1-deficient but not in caveolin 
2-deficient murine cells 25,26. In addition to BKPyV, SV40 and MPyV are also thought to take 




infects cells via clathrin-dependent endocytosis 28. The clathrin protein complex is a triskelion 
comprised of three heavy chains and three light chains 29. Clathrin complexes are not capable of 
directly interacting with the plasma membrane. Adaptor proteins are required to recruit clathrin 
complexes to clathrin pits on the membrane, where the legs of the clathrin triskelions further 
interdigitate to form a lattice. The clathrin-coated pit pinches off from the plasma membrane 
with the help of dynamin to form clathrin-coated vesicles. Silencing clathrin heavy chain 
expression with siRNA impairs clathrin-coated pit formation 30. 
In order to address the possibility that BKPyV, SV40, and mouse polyomavirus may 
establish infection in the same pathway that is independent of caveolin and clathrin, we re-
examined the BKPyV entry process in renal proximal tubule epithelial (RPTE) cells, the natural 
host cell for BKPyV. By treating cells with drugs and silencing caveolin 1, caveolin 2, clathrin 
heavy chain, and UDP-glucose ceramide glucosyltransferase (UGCG), we showed that BKPyV 
infection requires gangliosides but enters RPTE cells through a caveolin- and clathrin-
independent pathway. 
Results 
Our lab has previously shown that BKPyV interacts with liposomes containing 
gangliosides GD1b and GT1b, and that adding these gangliosides to non-permissive LNCaP cells 
makes them permissive for BKPyV infection 8. In order to continue examination of the role of 
gangliosides during BKPyV infection of human renal proximal tubule epithelial (RPTE) cells, an 
siRNA pool targeting UDP-glucose ceramide glucosyltransferase (UGCG) was transfected into 





Figure 2.1: UGCG catalyzes cerebroside synthesis. 
UGCG catalyzes the glycosylation step, transforming ceramide to cerebroside. Cerebroside is 
then used to synthesize gangliosides such as GM1, GD1b and GT1b. Sialic acids are α2-3 linked 





transforms it into cerebroside, which is required for all ganglioside synthesis (Figure 2.1). 
Galactose, N-acetyl-galactosamine, and sialic acid are then added to cerebroside in order to 
synthesize gangliosides. Because a quality UGCG antibody was not available, RT-qPCR was 
performed to confirm efficient knockdown of UGCG. The RNA samples were harvested at two 
days post transfection, and UGCG mRNA expression was normalized to glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) mRNA. Compared to the no siRNA and the non-targeting 
siRNA controls, UGCG mRNA levels were reduced by more than 90% (Figure 2.2A).  
We next tested the effect of knocking down UGCG on BKPyV infection. Human RPTE 
cells were transfected with no siRNA, a non-targeting siRNA pool, or a UGCG siRNA pool. 
Cells were infected with BKPyV at a MOI of 0.5 IU/cell, and at 48 hours post infection cell 
lysates were collected, resolved by SDS-PAGE, blotted, and assayed for TAg and GAPDH. The 
siRNA pool targeting UGCG reduced viral infection (Figure 2.2B). To further confirm that 
GD1b and GT1b are receptors for BKPyV infection in human RPTE cells, a rescue assay was 
performed. RPTE cells were transfected with the UGCG siRNA as described above. 10 hours 
prior to infection, gangliosides GM1, GD1b, or GT1b were added to the media, during which 
time the gangliosides incorporate into the cell membranes. Free gangliosides were removed by 
aspirating off the media and washing the cells with fresh media immediately before viral 
infection. Cells were infected and TAg expression was visualized by Western blotting. When 
siRNA that did not target UGCG was used and the gangliosides were subsequently added to the 
cells, the infection level stayed the same (Figure 2.2B). When the UGCG level was reduced, 
adding GM1, the receptor for SV40, did not restore infection as measured by TAg expression. 





Figure 2.2: UGCG knockdown and rescue assays. 
 (A) Normalized expression of UGCG mRNA (mean ± SEM). RPTE cells were transfected with 
non-targeting siRNAs or siRNAs targeting UGCG. Total RNA was collected, and reverse 
transcription and quantitative PCR were performed. UGCG mRNA expression was normalized 
to GAPDH mRNA. (B) RPTE cells were transfected with non-targeting siRNAs or siRNAs 
targeting UGCG. Gangliosides were added at 38 hours post transfection. At 48 hours post 
transfection, cells were infected with BKPyV at an MOI of 0.5 IU/cell. Western blotting was 





the same level as the untransfected control. These results confirm the previous finding that 
gangliosides GD1b and GT1b serve as receptors for BKPyV entry in human RPTE cells. 
After examining the receptor used by BKPyV in RPTE cells, we next wanted to see if 
cholesterol is required for BKPyV virus infection. Cholesterol regulates the conformation of 
gangliosides in the plasma membrane 11,31, and the oligosaccharide orientation could be essential 
for BKPyV attachment. A previous experiment showed that depleting cholesterol in Vero cells 
blocked BKPyV infection 12. In order to confirm this in RPTE cells, we tested the effect of 
methyl-β-cyclodextrin (MβCD) and nystatin in RPTE cells. Both MβCD and nystatin are 
cholesterol-depleting reagents that have been previously applied in polyomavirus studies. MβCD 
and nystatin block cholesterol function in different ways: MβCD physically extracts cholesterol 
from the plasma membrane and releases cholesterol into the media 32,33; in contrast, nystatin only 
binds to and forms a complex with cholesterol in the plasma membrane 34. In order to test the 
cytotoxicity of MβCD and nystatin, RPTE cells were treated with nystatin or MβCD at various 
concentrations for two days (Figure 2.3C). Cell viability was evaluated with a cell viability assay 
(WST-1 assay) after the treatment. Viable cells have a higher O.D. value in the viability assay. 
RPTE cells were able to tolerate both nystatin and MβCD at most of concentrations except 
treatment of MβCD at 5 mM. Next, RPTE cells were treated with nystatin or MβCD for 1 hour 
prior to the BKPyV infection (MOI 0.5). Drugs were removed and cell were washed with fresh 
media immediately before BKPyV infection. After virus absorption for one hour, nystatin or 
MβCD were added back to the media. Infected cells were cultured for additional two days under 
drug treatments, and protein samples were harvested at 48 hours post infection. Proteins were 







Figure 2.3: The effects of inhibitors on BKPyV infection. 
(A) RPTE cells were treated with indicated drugs for 1 hour prior to BKPyV inoculation (MOI 
0.5). Protein samples were collected at 48 hours post infection. Western blotting was performed 
on harvested protein samples. (B) RPTE cells were treated with indicated drugs for 1 hour prior 
to BKPyV inoculation (MOI 5). Protein samples were collected at 24 hours post infection (hpi) 
unless labeled otherwise. Western blotting was performed on harvested protein samples. (C) 





Interestingly, MβCD treatment significantly blocked BKPyV infection; however, nystatin did not 
affect BKPyV infection at all (Figure 2.3A). 
Beside cholesterol, actin filaments also have an impact on BKPyV infection in Vero cells 
15. To confirm this in RPTE cells, actin filaments were disassembled with cytochalasin D, and 
actin filament disassembly was confirmed with phalloidin staining (Figure 2.4A-F). RPTE cells 
were then treated with cytochalasin D at various concentrations that had been tested to be non-
toxic (Figure 2.4G). RPTE cells were infected with BKPyV (MOI 5) at 4˚C, and protein samples 
were harvested at 24 hours post infection unless indicated otherwise. When RPTE cells were 
treated at lower concentrations (lower than 500 nM) with cytochalasin D, phalloidin staining 
indicated that actin filaments were only partially disassembled (Figure 2.4A-D); however, 
BKPyV infection was slightly increased (Figure 2.3B). On the other hand, cytochalasin D at 
higher concentrations (500 nM or higher) significantly blocked actin filament assembly (Figure 
2.4 E,F), and it also blocked BKPyV infection (Figure 2.3B). Genistein, a tyrosine kinase 
inhibitor, blocks BKPyV entry in Vero cells 12. Its inhibitory effect in RPTE cells was also 
examined. At one day post infection, genistein completely blocked BKPyV entry in RPTE cells 
(Figure 2.3B). The experiments described above showed that BKPyV did not behave in exactly 
the same manner in natural host cells as it did in Vero cells. Next, whether BKPyV would follow 
a caveolin-dependent pathway in RPTE cells was tested. Caveolae have been reported to guide 
BKPyV entry in Vero cells 12. In order to test whether BKPyV infects RPTE cells via the same 
endocytic pathway, caveolin 1 or caveolin 2 siRNA pools were transfected into cells. Each 
siRNA pool contained four unique siRNAs targeting the designated human mRNA. At 48 hours 
post-transfection, protein lysates were collected, resolved by SDS-PAGE, and probed for 





Figure 2.4: The effects of Cytochalasin D on actin filaments.  
RPTE cells were treated for 1 hour with vehicle (DMSO, panel A) or 30 nM (B), 120 nM (C), 
500 nM (D), 1 µM (E), or 2 µM (F) cytochalasin D, followed by staining with phalloidin. (G) 
RPTE cells were treated with cytochalasin D at indicated concentration for 24 hours, and cell 





2 siRNA transfection showed corresponding protein expression reduction, suggesting that the 
siRNA transfection was successful. However, an obvious off-target effect was also observed 
with caveolin 1-transfected RPTE cells. The caveolin 1 siRNA pool knocked down not only 
caveolin 1, but also caveolin 2 (Figure 2.5B). To eliminate the off-target effect from the caveolin 
1 pool, the four siRNAs from this pool were transfected into RPTE cells individually to 
determine which siRNAs would knock down caveolin 1 but not caveolin 2. Analyzing protein 
samples from cells transfected with the individual siRNAs showed that siRNA #4 was the only 
siRNA that was capable of knocking down caveolin 1 without affecting caveolin 2 (Figure 
2.5A).  
To test the role of caveolin 1 or caveolin 2 during viral entry, caveolin 1 siRNA #4 or the 
caveolin 2 siRNA pool were transfected into RPTE cells. Transfection with no siRNA and the  
non-targeting siRNA pool were used as negative controls, and the siRNA pool targeting UGCG 
or an siRNA targeting TAg were positive controls. Cells were cultured for two days after 
transfection in order to deplete the targeted proteins and then infected with BKPyV. Two days 
post infection, cell lysates were collected and TAg and caveolin protein expression were 
evaluated by Western blotting. The Western blotting confirmed that the caveolin 1 siRNA #4 and 
the caveolin 2 siRNA pool successfully reduced caveolin 1 or caveolin 2 protein levels 
respectively (Figure 2.5B). The siUGCG pool and the siRNA targeting TAg both reduced TAg 
expression as expected. Surprisingly, knocking down caveolin did not increase or decrease 
BKPyV infection. These results suggest that BKPyV infection is independent of caveolin 1 or 





Figure 2.5: Caveolin protein knockdown and BKPyV entry. 
(A) Cross-reactivity of siRNAs targeting caveolin 1 and caveolin 2. Individual siRNAs targeting 
caveolin 1 and an siRNA pool targeting caveolin 2 were transfected into RPTE cells. Caveolin 
expression at 2 days post infection was examined by Western blotting. (B) Caveolin protein 
knockdown does not affect BKPyV infection. RPTE cells were transfected with the indicated 






Caveolin- and clathrin-dependent endocytic pathways are two major pathways that form 
small vesicles 22. Clathrin-dependent endocytosis has been reported to be essential for JCPyV 
entry 28. Since caveolins were not required for BKPyV entry into RPTE cells, we next examined 
if the clathrin-dependent pathway plays a role in BKPyV infection. To deplete clathrin, an 
siRNA pool targeting clathrin heavy chain was introduced into RPTE cells. BKPyV infection 
was evaluated as previously described. Compared to the no siRNA control and the non-targeting 
siRNA control, clathrin heavy chain was knocked down efficiently (Figure 2.6A). However, viral 
infection was not affected, indicating that BKPyV does not infect human RPTE cells by a 
clathrin-dependent pathway, consistent with the previous report from Moriyama et al 13. In 
addition, we tested the possibility that both caveolin- and clathrin-dependent pathways could be 
involved during BKPyV endocytosis, and inhibiting one pathway can be compensated by the  
other pathway. To test this scenario, we transfected siRNA pools targeting clathrin heavy chain 
and the two caveolins into RPTE cells, and viral infection was evaluated. Similar to the single 
knockdowns, BKPyV infection was not affected compared to non-targeting control by knocking 
down caveolin 1, caveolin 2 and clathrin heavy chain at the same time (Figure 2.6B). 
Norovirus also attaches to the plasma membrane with gangliosides 35 and enters host cells 
via a caveolin- and clathrin independent pathway 36. In this study, Perry et al. demonstrated that 
dynamin II was involved in norovirus endocytosis. We therefore tested whether BKPyV entry is 
also dependent on dynamin II. RPTE cells were inoculated with BKPyV. After inoculation, 
NH4Cl or Dynasore, a dynamin inhibitor 37, was added to infected cells at the indicated time 
points post infection. Protein samples were harvested and processed as previously described. The 
toxicity of NH4Cl or Dynasore was also tested (Figure 2.7B). Our laboratory has previously 






Figure 2.6: Clathrin heavy chain knockdown and BKPyV entry. 
(A) RPTE cells were transfected with the indicated siRNAs, and viral infection and clathrin 
heavy chain expression levels were examined by Western blotting. (B) RPTE cells were 






Figure 2.7: The effects of dynamin inhibitor on BKPyV infection. 
(A) RPTE cells were inoculated with BKPyV (MOI 0.5). Dynasore (40µM) or NH4Cl (6.25mM) 
were added at indicated time points. Protein samples were collected at 48 hours post infection. 
Western blotting was performed on harvested protein samples. (B) RPTE cells were treated with 





added before 2 hours post infection 18, which was reproduced in this experiment (Figure 2.7A). 
Surprisingly, Dynasore blocked BKPyV infection when added up to 12 hours post infection 
(Figure 2.7A). At 12 hours post infection, BKPyV has already arrived at the ER, suggesting that 
Dynasore blocks a later step of BKPyV infection.  
Discussion 
BKPyV directly causes allograft failure among at least 1% of kidney transplant patients 
worldwide. Moreover, BKPyV can causes painful HC in hematopoietic cell transplant patients. 
Unfortunately, specific antiviral drugs are not currently available, and the only management 
available is withdrawing immunosuppression in PVAN patients, which risks acute rejection, or 
palliative care in HC patients. Due to the fact that BKPyV uses the host DNA synthesis 
machinery for its genome replication, one possible effective strategy to protect cells from 
infection would be targeting critical host factors required by BKPyV before it delivers its DNA 
genome into the nucleus of the host cell. Therefore, understanding the trafficking pathway that 
BKPyV undergoes is not only important for understanding viral biology but also potentially 
important for identifying drug targets. 
The trafficking pathways of polyomaviruses have been extensively studied since the 
initial isolation of murine polyomavirus (MPyV) in 1953 38. Polyomaviruses have been shown to 
use three pathways to infect host cells: caveolin-dependent 12,13, clathrin-dependent 28, or 
caveolin- and clathrin-independent 4,6. With BKPyV, most of the initial trafficking studies were 
carried out using non-human animal cell models because of a lack of relevant human cell models 
at the time. Those studies indicated that BKPyV infects monkey cells via a caveolin-dependent 




process might be cell type- or species-specific. First, SV40, MPyV, and cholera toxin B subunit 
had been originally considered to enter cells via a caveolin-dependent pathway 2,27,39,40, but 
subsequent studies showed that SV40, MPyV, and cholera toxin are able to enter caveolin 1-
deficient cells 3,4,6,41,42. Second, our lab showed that SV40 trafficking is cell type-dependent 20. 
Third, an in vitro study showed that the 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) 
reductase inhibitor Pravastatin, which inhibits cholesterol synthesis, prevents BKPyV infection 
by depleting caveolin 1 protein in RPTE cells 43; however, a clinical trial using Pravastatin failed 
to protect patients from PVAN at the maximum effective dose 44. Lastly, a study focused on 
BKPyV trafficking in human kidney cells supported the previous animal model that BKPyV 
entry is caveolin-dependent 13; however, we were unable to reproduce the results of Moriyama et 
al. by exactly following their reported protocol. In fact, our caveolin depletion was at least two 
fold more efficient than theirs, and viral infection was evaluated as early as one-day post 
infection versus five days post infection as they tested. Considering that 100 nM siRNA was 
applied in their experiment setting, the phenotype they observed could be an off-target effect of 
the concentrated siRNA. 
These findings inspired us to re-examine BKPyV entry into RPTE cells. Our results 
demonstrate that BKPyV does behave differently when infecting RPTE cells than it does in 
monkey cells. The cholesterol-depleting reagent MβCD blocked BKPyV infection as previously 
tested in Vero cells 12, however, another cholesterol depleting reagent, nystatin, did not block 
BKPyV infection in RPTE cells at all. Actin filament disassembly upon latrunculin A treatment 
did not affect BKPyV infection in Vero cells. However, another actin assembly inhibitor, 
cytochalasin D, slightly increased BKPyV infection of RPTE cells at lower concentrations 




Dynasore, a dynamin II inhibitor, blocked viral entry as expected, however, it could still block 
BKPyV infection even after viruses reached the ER. The effects of inhibitor treatments were 
more complicated than our original expectations, and drugs that have similar function showed 
totally conflicting effects on BKPyV entry. Although we confirmed the inhibitory effect of 
genistein in RPTE cells, genistein regulates too many pathways to make any conclusion about a 
particular pathway 45,46. It suggests that more care is required when interpreting drug treatment 
results.  
By transfecting siRNAs targeting caveolin 1 or caveolin 2, we reduced caveolin 1 or 
caveolin 2 expression in RPTE cells without affecting BKPyV infection. We also tested if 
BKPyV infects RPTE cells using clathrin-coated vesicles, as JCPyV does in the human glial cell 
line SVG 28. Similar to the caveolin knockdown, there was no obvious difference in infection 
between clathrin heavy chain-depleted cells versus control cells. In order to eliminate the 
possibility that BKPyV enters RPTE cells via both caveolin- and clathrin-dependent pathways, 
the two caveolins and clathrin heavy chain were knocked down together, and when we 
challenged the transfected cells with BKPyV, no change in BKPyV infection was observed. In 
addition, our UGCG knockdown data confirmed previous findings from our lab that gangliosides 
GD1b and GT1b serve as receptors for BKPyV in primary RPTE cells. We saw a reproducible 
slight increase in infection in cells transfected with the non-targeting siRNA pool. It suggests 
that the non-targeting siRNA pool also has an off-targeting effect. 
Several caveolin- and clathrin-independent pathways that could assist BKPyV entry have 
been reported, such as RhoA/Rac1 47, Cdc42 48,49, ARF6 50, and flotillin 51 mediated endocytosis. 
Considering that polyomavirus enters tight fitting vesicles after endocytosis 6,14,52, and actin 




likely to infect RPTE cells by a yet uncharacterized endocytic pathway, since most of the 
endocytic pathways listed above are associated with actin polymerization 53-56. 
In addition to protein-dependent endocytic pathways, it is possible that BKPyV enters 
host cells using a lipid-mediated endocytosis pathway in which cholesterol and gangliosides 
alone may be sufficient to initiate entry. An in vitro assay showed that artificial liposomes with 
cholesterol and gangliosides, called giant unilamellar vesicles, can form caveolae-like vesicles 
without the addition of any host proteins 57. A later study showed that SV40 was able to induce 
deep invaginations on the surface of these vesicles 58, suggesting that entry could be vesicle coat 
protein-independent. In that scenario, the virus-containing tight fitting vesicles might be formed 
by multiple direct interactions between gangliosides and the VP1 capsid protein, with cholesterol 
stabilizing the vesicle membrane invagination. Further studies are required to fully define the 
BKPyV endocytosis process. 
In summary, we have demonstrated that BKPyV enters its natural host cell via a 
caveolin- and clathrin-independent pathway, and we have confirmed that gangliosides 
GD1b/GT1b serve as receptors. Additional studies will be required to determine the role of 
additional cellular proteins in the viral entry and trafficking processes. 
Materials and Methods 
Cell culture. Primary renal proximal tubule epithelial cells (RPTE) (Lonza) were grown 
in renal epithelial basal growth medium (REBM) (Lonza) with renal epithelial cell growth 





Drug treatment. Nystatin (Sigma) and methyl-β-cyclodextrin (MβCD, Sigma) were 
kindly provided by Christiane Wobus (University of Michigan). Nystatin was suspended at 50 
mg/ml in cell culture grade water. MβCD was dissolved in cell culture grade water at 30 mM. 
Dynasore (Sigma) was dissolved in DMSO at 20 mM. Cytochalasin D (Sigma) was dissolved in 
DMSO at 1 mM. NH4Cl (Fisher) was dissolved in cell grade water at 1 M and filtered with a 
0.22 µm filter. Genistein (Sigma) was dissolved in DMSO at 50 mM. Drugs or vehicle were 
directly added to the cell culture media at indicated concentrations and time points. 
 
Phalloidin staining. RPTE cells were grown on coverslips in a 12 well plate. After drug 
treatment, cells were fixed with 4% paraformaldehyde (PFA) in PBS at room temperature for 10 
minutes. After fixation, cells were permeabilized with 0.1% Triton X-100 in PBS at room 
temperature for 5 minutes. Next, cells were stained with 1 unit Alexa Fluor 488 phalloidin 
(Thermo) in 200 µl PBS for 20 minutes at room temperature. The coverslips were mounted in 
Prolong Gold with DAPI (Thermo) onto microscope slides (Thermo). Cells were washed with 
PBS three times between each staining step. 
  
Transfection. siGENOME siRNA pools and individual siRNAs were purchased from 
Dharmacon: Non-targeting control (D-001206-14); Caveolin 1 (M-003467-01); Caveolin 2 (M-
010958-00); UGCG (M-006441-02); Caveolin 1 #1 (D-003467-01); Caveolin 1 #2 (D-003467-
02); Caveolin 1 #3 (D-003467-03); Caveolin 1 #4 (D-003467-05); Clathrin heavy chain (M-
004001-00). siRNA targeting large T antigen was custom synthesized with the sequence (5’ 
AUCUGAGACUUGGGAAGAGCAU 3’), which corresponds to the natural BKPyV 5p miRNA 




Dharmacon. RPTE cells were transfected according to the Lipofectamine RNAiMAX (Thermo 
Fisher Scientific) manual. Transfection complexes were prepared by mixing 1 µl of 20 µM 
siRNA with 400 µl of diluted transfection reagent (0.7% RNAiMAX reagent v/v in 
REBM/REGM without antibiotics) in each well of a 12 well plate. The complexes were 
incubated at room temperature for 20 min before adding 70,000 cells suspended in 400 µl 
REBM/REGM without antibiotics to each well.  
 
Infection. BKPyV (Dunlop) was cultured, purified with a cesium chloride linear 
gradient, and titered as described previously 18,60. RPTE cells were infected as follows at 2 days 
post transfection. Cells were pre-chilled for 15 min at 4˚C. Purified viruses were diluted to 
87,500 IU/ml (MOI 0.5) or 875,000 IU/ml (MOI 5) in REBM/REGM. 400 µl of the diluted virus 
were added to the wells and incubated at 4˚C for 1 hour with shaking every 15 minutes to 
distribute the inoculum over the entire well. The plate was transferred to 37˚C after the 1-hour 
incubation. 
 
Ganglioside treatment. Gangliosides GM1, GD1b, and GT1b (Matreya) were kindly 
provided by Billy Tsai (University of Michigan). Gangliosides were rehydrated at 1 mM in cell 
culture grade water. 10 hours prior to infection, gangliosides were added directly to the media at 
1 µM. At the time of infection, media with gangliosides was removed and cells were washed 
with fresh media to remove the unincorporated gangliosides. 
 
Preparation of protein lysates. Cells were lysed at 48 hours post infection with E1A 




5 µg/ml aprotinin, 5 µg/ml leupeptin, 50 mM sodium fluoride and 0.2 mM sodium orthovanadate 
added right before use). Protein concentration was quantified with the Bradford assay (Bio-Rad). 
 
Western blotting. Protein samples were separated on 12% SDS-PAGE gels. After 
electrophoresis, the proteins were transferred to a nitrocellulose membrane (pore size 0.2 µm) 
with a Bio-rad Trans-Blot Cell in Towbin transfer buffer (25 mM Tris, 192 mM glycine, 20% 
methanol), at 60 V overnight. Membranes were blocked with 2% nonfat milk in PBS-T buffer 
(144 mg/L KH2PO4, 9 g/L NaCl, 795 mg/L Na2HPO4, pH 7.4, 0.1% Tween 20) for 1 hour. 
Membranes were probed with primary and secondary antibodies diluted in 2% milk in PBS-T as 
follows: TAg (pAb416) at 1:5,000 dilution 61; GAPDH (Abcam ab9484) at 1:10,000; caveolin 1 
(Santa Cruz SC-894) at 1:20,000; caveolin 2 (Cell signaling #8522) at 1:5,000; clathrin heavy 
chain (Thermo Fisher Scientific, MA1-065) was kindly provided by Christiane Wobus 
(University of Michigan), used at 1:10,000, horseradish peroxidase (HRP)-conjugated ECL 
sheep anti-mouse (GE healthcare NA931V) at 1:5,000; and HRP-conjugated ECL donkey anti-
rabbit antibody (GE healthcare NA934V) at 1:5,000. Protein bands were further visualized with 
HRP substrate (Millipore, WBLUF0100) and exposure to films. 
 
Reverse transcription and quantitative PCR (RT-qPCR). At 48 hours post 
transfection, cellular RNA was harvested with TRIzol RNA isolation reagent (Thermo Fisher 
Scientific) and further purified according to the manual for the Zymo Research Direct-zol RNA 
MiniPrep kit. 100 ng of RNA was treated with 1 unit of DNase I (Promega) and cDNA was 
prepared according to the SuperScript II Reverse Transcriptase (Thermo Fisher Scientific) 




(5’ GCCTCAAGATCATCAGCAAT 3’) and (5’ CTGTGGTCATGAGTCCTTCC 3’), UGCG 
(5’ AGACACCTGGGAGCTTGCTA 3’) and (5’ TTCGTCCTCTTCTTGGTGCT 3’). UGCG or 
GAPDH expression in each cDNA sample was quantified in 25 µl reactions and in triplicate. 
Each reaction was comprised of 2.5 µl of cDNA, 12.5 µl of Power SYBR green PCR master mix 
(Applied Biosystems), 300 nM of each primer, and nuclease free water (Promega). Amplification 
was performed using the iCycler iQ5 real-time detection system (Bio-Rad) with the following 
PCR protocol settings: 2 min at 50°C, 10 min at 95°C, 40 cycles of 15 s at 95°C and 30 s at 
57°C. SYBR green signal intensity was read immediately after each 57˚C extension. 
Note 
Parts of this chapter were previously published: Zhao L, Marciano AT, Rivet CR, 
Imperiale MJ. 2016. Caveolin- and clathrin-independent entry of BKPyV into primary human 
proximal tubule epithelial cells. Virology. 492:66-72. 
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Whole genome RNA interference screen for host genes associated with 
BKPyV infection
Abstract 
BK polyomavirus (BKPyV) is a human pathogen first isolated in 1971. The mature 
BKPyV particle is about 45 nm in diameter and contains a 5.2 kb circular dsDNA genome. 
BKPyV infection is ubiquitous in the human population, with over 80% of the adult population 
worldwide seropositive for BKPyV. BKPyV infection is usually asymptomatic; however, 
BKPyV reactivates in immunosuppressed transplant patients and causes two diseases, 
polyomavirus associated nephropathy (PVAN) and hemorrhagic cystitis. Due to a lack of 
specific antiviral drugs, the first-line treatment for BKPyV reactivation is to reduce 
immunosuppression in PVAN patients, thereby increasing the likelihood of graft rejection; 
therefore, elucidating details of the BKPyV life cycle will potentially benefit clinical practice and 
therapy development in addition to uncovering interesting viral and cell biology. 
In order to establish a productive infection, viruses have developed multiple strategies to 
set up a permissive environment for replication. This requires interactions between various viral 
components and host cell proteins. Whole-genome high-throughput siRNA screening provides a 
tool to investigate potential virus-host interactions. By silencing every single human gene with 




able to dissect the functions of individual host proteins during the viral life cycle. To further 
identify host factors associated with BKPyV entry and intracellular trafficking, a whole genome 
siRNA screen was performed on BKPyV in human primary renal proximal tubular epithelial 
(RPTE) cells. DNAJ B14, which has previously been implicated in BKPyV entry, is our top hit, 
and DNAJ B12 is also among our top 100 hits. The other hits we identified have not been 
previously reported; however, many of them are involved in vesicular transport. After validation, 
Rab18, STX18 protein, and the NRZ protein complex are identified to be essential for BKPyV 
infection. Considering that all of these proteins form a complex on the ER membrane and 
participate in Golgi to ER trafficking, the Golgi to ER pathway may play an important 
previously-undiscovered role in BKPyV infection.  
Introduction 
BK polyomavirus (BKPyV) is a small DNA icosahedral virus measuring about 45 nm in 
diameter, and was first isolated in 19711. Subsequent serology surveys revealed that up to 80% 
of the world’s population has been infected with BKPyV 2, and most of the initial infections 
occur in early childhood 3. Fortunately for most healthy individuals, the immune system limits 
BKPyV infection, and BKPyV infection is usually asymptomatic. After initial exposure, BKPyV 
establishes a persistent infection in the urinary tract with periodic shedding into the urine 4. 
BKPyV reactivates when the immune system is compromised in transplant patients, and it causes 
two diseases: polyomavirus-associated nephropathy (PVAN) and hemorrhagic cystitis (HC). 
PVAN is one of the major causes of graft failure after kidney transplantation 5. In addition, 
BKPyV can be detected in the urine of 90% of allogeneic hematopoietic cell transplant patients 




Despite the fact that BKPyV was initially isolated more than 40 years ago, the choices for 
clinical management of BKPyV reactivation are limited. Because the viral genome does not 
encode any polymerase, BKPyV relies exclusively on the host DNA replication machinery for 
viral genome replication; therefore, most common therapeutic strategies targeting viral 
polymerases are not applicable. The first-line treatment for PVAN is lowering the dosage of 
immunosuppressants, which inevitably increases the risk of acute rejection and graft failure 5. 
Other options for treating BKPyV besides withdrawing immunosuppressants are cidofovir, 
leflunomide, and fluoroquinolones, drugs that inhibit BKPyV infection through modulating the 
host cell DNA replication machinery. However, they are not good options because of their 
cytotoxicity. Therefore, no specific antiviral drug is currently available for BKPyV reactivation.  
 To establish a successful infection, BKPyV must deliver its DNA genome into the 
nucleus in order to access the host DNA replication machinery, which means penetrating the 
plasma membrane, the ER membrane, and the nuclear envelope. In addition, BKPyV has to 
traffic to the ER through a crowded cytoplasm. Without any help from host factors, this process 
would seem impossible. In order to block BKPyV infection, one possible strategy would be to 
target host factors that assist viral entry or intracellular trafficking before the virus manages to 
deliver its genome to the nucleus. 
Many host factors have been demonstrated as playing important roles after BKPyV 
delivers its genome into the nucleus, such as p53 7, pRB 8, ATM, and ATR 9. However, few host 
factors have been identified as assisting viral entry and intracellular trafficking. Polyomavirus 
takes advantage of multiple pathways to enter the host cell, and some of the pathways are non-
productive 10. Distinguishing the critical pathway that BKPyV takes to establish successful 




productive pathways and limited specific inhibitors, some experiments performed with 
immunofluorescent staining and drug treatments are unreliable and misleading.  
Both SV40 and murine polyomavirus (MPyV) have been considered to enter the cell via 
a caveolin-mediated pathway 11,12, however, subsequent experiments revealed that caveolin was 
completely dispensable for successful infection 13-15. In the previous chapter, evidence is 
provided suggesting that BKPyV, as had been also reported for SV40 and MPyV, does not 
require caveolin to infect renal proximal tubular epithelial (RPTE) cells. In order to reveal the 
true pathway that BKPyV takes in the early stages of infection, another approach to identify host 
factors involved in the early stages of BKPyV infection that avoids the limitations of the 
previous experiments, which were based on morphological changes and drug treatments, is 
needed. 
Numerous assays have been developed for the purpose of identifying host factors 
associated with viral infections, including one of the most widely used assays: genome-wide 
siRNA screening. RNA interference (RNAi) was first discovered in plant cells in 1986 16. 
Twelve years later, siRNA, a short double stranded RNA, was reported as a potential tool for 
biological research 17. Barely two years after the introduction of siRNA methods, genomic 
siRNA screens were performed in C. elegans 18. After the completion of the human genome 
project in 2006, whole genome siRNA screening in humans became possible. By silencing every 
single human gene with an siRNA pool, and then assessing the effects of the knockdown on 
infection, it is possible to dissect the functions of individual host proteins during the viral life 
cycle. siRNA screening has been extensively applied to research on virus, such as HIV 19, West 
Nile virus 20, HPV 21, VSV 22, and another polyomavirus, SV40 23. However, no genome-wide 




we identified a series of potential host factors that may be involved in BKPyV infection. By 
further validating our primary hits, RAB18, STX18, and two members of the NRZ complex were 
identified as host factors that are essential for BKPyV infection. 
Rab18 is a Ras-like GTPase that regulates retrograde trafficking from the Golgi to the ER 
24,25. Rab18 usually localizes to the membrane of the ER and the Golgi apparatus 24. Upon 
overexpression, Rab18 also localizes to lipid droplets and may localize to the endosome 26. 
Rab18 interacts with STX18 protein and the NRZ protein complex in cells 27. STX18 protein 
functions as a t-SNARE on the ER membrane where the NRZ complex works as a tether 
complex assisting retrograde vesicle docking 28,29. All of these proteins work together in 
capturing targeted vesicles and in initiating the fusion process on the ER membrane. Our screen 
results suggest that BKPyV enters the ER via a vesicle fusion step, and trafficking from the 
Golgi to the ER may play an important role in efficient BKPyV infection. 
Results 
siRNA screen assay development. 
Morphology studies have only suggested a basic model of the BK polyomavirus 
(BKPyV) life cycle, and therefore details of the early stages of the BKPyV life cycle remain to 
be elucidated. In order to identify host factors involved in viral entry and intracellular trafficking, 
a whole genome siRNA screen was developed for the BKPyV Dunlop strain in its natural host 
cell line, human primary renal proximal tubule epithelial (RPTE) cells.  
A two-step screen approach is commonly used for this type of screen. In the first step, 
host cells are transfected with siRNA pools from an siRNA library, and targeted proteins are 




are challenged with virus and viral infection is evaluated with a proper readout suitable for large-
scale experimentation.  
Our lab previously showed that BKPyV induces G2/M arrest in order to fully take 
advantage of the host cell DNA replication machinery 9, which provides us with a cost efficient 
approach to evaluate viral infection in siRNA-transfected cells. By applying a simple Hoechst 
DNA stain, cells in G2/M phase can be easily distinguished from the rest of the cells based on 
the difference in DNA content in each nucleus. The percentage of G2/M arrested cells (G2%) in 
the whole cell population can then be calculated and serve as a readout for the screen assay.  
To optimize the primary screen assay, RPTE cells were transfected with non-targeting 
siRNA or a custom synthesized siRNA targeting the TAg mRNA (siTAg), which corresponds to 
the natural BKPyV 5p miRNA 30. After a 48-hour culture, transfected RPTE cells were 
challenged with purified BKPyV. At 48 hours post infection, cells were fixed and permeabilized 
with Triton X-100. The nuclei were visualized with Hoechst stain. Cell images were acquired 
with a high-throughput microscope and analyzed with a cell cycle module from ImageXpress 
high-content image analysis software. Using the software, cells arrested in G2/M phase were 
identified based on nuclear DNA content. (G2% values were calculated and illustrated in Figure 
3.1A). Compared to mock infected cells, BKPyV infection significantly increased the present of 
G2/M cells. This was completely abolished by introducing siTAg to RPTE cells. The Z’ factor is 
used to describe the quality of an assay. The Z’ factor is usually smaller than 1.0, with 1.0 being 
the optimum. A minimal Z’ factor of 0.5 is required for an siRNA screen assay 31. After further 
optimizing transfection and infection conditions, our assay reached a Z’ factor of 0.77, which is 






Figure 3.1: Primary screen assay development. 
(A) RPTE cells were transfected with a non-targeting siRNA control or an siRNA targeting viral 
early protein large tumor antigen. Cells were infected with BKPyV at 48 hours post transfection, 
then fixed and stained with Hoechst at 48 hours post infection. Cells in G2/M phase were 
identified with image analysis software and the percentage of cells arrested in G2/M phase 
(G2%) was calculated. (B) RPTE cells were transfected with a non-targeting siRNA control or 
an siRNA targeting viral early protein TAg. Cells were inoculated with BKPyV at 48 hours post 
transfection, and then fixed and immunofluorescently stained for TAg at 48 hours post infection. 





To optimize the validation assay, RPTE cells were transfected, infected, and fixed as 
described above. After fixation, cells were immunofluorescently stained for TAg. Images of the 
cells were acquired and analyzed with the multi-wavelength cell scoring module from 
ImageXpress analysis software. Average fluorescent intensity per nucleus was quantified (Figure 
3.1B). A Z’ factor of 0.55 was achieved after optimization. Both rounds of screening met the 
sensitivity and accuracy requirements for siRNA screening in triplicate 31. 
Primary whole genome siRNA screen on BKPyV in RPTE cells. 
After the development of both assays, the primary screen protocol was adapted to an 
automated workstation. Each siRNA pool from the siGENOME siRNA library, containing 
18,100 human genes, was aliquoted and transferred to three clear-bottom 384 well plates. RPTE 
cells were transfected and cultured for 48 hours to deplete the targeted proteins. Next, cells were 
infected with BKPyV. The G2% values were quantified, recorded, and uploaded to the MScreen 
web tool developed by the Center for Chemical Genomics (University of Michigan). To begin 
the analysis, we arbitrarily set the inhibitory effect of the siTAg as 100%, and the inhibitory 
effect of non-targeting siRNA control as 0%. The inhibitory effect of each siRNA pool was 
calculated accordingly. A larger value represents a stronger inhibitory effect on BKPyV infection 
when an siRNA pool is introduced into RPTE cells, which also means that the targeted host 
factor is more likely to be required for BKPyV infection. After testing over 18,100 siRNA pools 
contained in the siGENOME library in triplicate, all the acquired data were plotted onto a 
histogram and a heat map (Figure 3.2). In this heat map (Figure 3.2B), the darkness of a colored 
bar indicates the inhibitory (blue) or enhancement (red) effect of an siRNA pool on BKPyV 
infection. Every three bars in the same row illustrate the results of one siRNA pool in triplicate. 





Figure 3.2: Histogram and heat map of the whole genome siRNA screen data. 
RPTE cells were transfected with a non-targeting siRNA control, siTAg control, or an siRNA 
pool in siGENOME library. Transfected cells were challenged with BKPyV. The percentage of 
cells arrested in G2/M phase (G2%) was calculated and converted into a scale in which siTAg 
transfected control was arbitrarily set as 100%, and the non-targeting control was set as 0%. (A) 
Histogram of the primary screen data. (B) Heat map of the primary screen data. Primary screen 
results of ~18,100 genes are illustrated in four columns, with each column representing 
approximately 4,500 genes. Each colored bar represents a data point. Three bars in the same row 




approximately 4,500 genes in triplicates. The histogram (Figure 3.2A) shows that the G2% data 
fit into a normal distribution centered at approximately 35%. Moreover, 70% of the siRNA pools 
tested inhibited BKPyV infection to some degree when compared to the non-targeting siRNA 
control. Similar results were also observed in an siRNA screen using the same siRNA library on 
papillomavirus infection 21.  
In order to illustrate the primary screen data in greater detail, the 300 top hits from both 
tails of the distribution were also plotted onto a separate heat map (Figure 3.3). Each colored bar 
represents a data point, and every three bars in the same row illustrate the inhibitory effect of one 
siRNA pool in triplicate. The heat map shows that the three replicates correlates well. The 
overall Z’ factor achieved in the primary screen is 0.6 and the Pearson product-moment 
correlation coefficient factors are 0.8-0.9 between replicates. DNAJ B14, which has previously 
been implicated in BKPyV entry, is our top hit, and DNAJ B12 is also among our top 100 hits 
23,32. Most of the other identified hits we have identified have not been previously reported, 
however, and many of them are involved in vesicular transport. 
DAVID enrichment analysis and validation 
The top 800 host factors that were most likely to affect BKPyV infection were uploaded 
to the Database for Annotation, Visualization and Integrated Discovery (DAVID) enrichment 
analysis tool (https://david.ncifcrf.gov). The analysis showed that translation-related genes were 
among the most enriched groups of genes that assist viral infection among the candidate genes 
(Table 3.1). Considering that BKPyV exclusively relies on the host protein synthesis machinery, 
this result is consistent with our expectation. 
Other than translation-related genes, several clusters of genes that may assist viral 





Figure 3.3: Heat map of the top hits from both tails. 
 Top 300 genes from both tails (600 genes in total) are illustrated in this heat map. Each colored 
bar represents a data point. Three bars in the same row illustrate the effects of one siRNA pool in 





associated with vesicle budding, and coat proteins located in the Golgi apparatus. Based on the 
enrichment analysis results and our interest, we manually selected 147 genes for validation 
(Table 3.2). 
G2% is an indirect readout for BKPyV infection as knockdown of cell cycle regulatory 
proteins may induce G2/M arrest spontaneously even without viral infection; thus false positive 
or false negative candidates could be introduced into the results. To eliminate these false 
candidates, we next applied a direct readout of virus infection during validation. As we 
previously developed and optimized, TAg immunostaining fluorescent intensity was applied as a 
direct readout to validate the 147 genes. RPTE cells were transfected with a custom siRNA 
library in triplicate (Table 3.2). Next, the transfected cells were cultured for 48 hours to deplete 
the targeted proteins. At 48 hours post transfection, cells were infected with BKPyV. Infected 
cells were fixed at 48 hours post infection and probed for TAg with primary antibody and FITC-
labeled secondary antibody. After acquiring images, integrated TAg fluorescent intensity per 
nucleus was recorded and the percentage of inhibition compared to the controls was calculated 
(Table 3.3). As previously described, the non-targeting control was set as 0%, and siTAg was set 
as 100%. Validation was performed in triplicate, and results from two repeats of the validation of 
147 genes were obtained (Figure 3.4). Every six colored bars in the same row illustrate 
validation results of one siRNA pool. In general, replicates in validation experiments are less 
correlated compared to the primary screen (Figure 3.3), probably due to variation introduced by 
the extra steps required for immunofluorescent staining versus Hoechst staining. Compared to 
the primary screening results (Figure 3.2B), the siRNA pools in the validation test were 




Table 3.1: DAVID enrichment analysis result. List of top enriched categories. 
 
Term P Values Fold Enrichment 
Translational elongation 2.68E-13 6.94 
Translation 2.07E-08 3.06 
Vesicle coating 8.47E-06 12.81 
Membrane budding 1.31E-05 12.01 
Golgi transport vesicle coating 1.35E-05 16.47 
COPI coating of Golgi vesicle 1.35E-05 16.47 
Golgi vesicle budding 1.35E-05 16.47 
Vesicle targeting, to, from or within Golgi 3.99E-05 13.73 
Vesicle targeting 1.02E-04 8.73 
Vesicle organization 4.63E-04 4.84 
Retrograde vesicle-mediated transport, Golgi to ER 7.80E-04 7.84 
Establishment of vesicle localization 1.07E-03 5.82 
Intracellular transport 1.38E-03 1.69 
Cellular protein localization 1.76E-03 1.90 
Cellular macromolecule localization 1.97E-03 1.89 
Vesicle localization 1.99E-03 5.19 





Table 3.2: List of genes selected for validation. 
Entrez ID Gene symbol Entrez ID Gene symbol Entrez ID Gene symbol 
87 ACTN1 5584 PRKCI 26270 FBXO6 
162 AP1B1 5611 DNAJC3 26272 FBXO4 
163 AP2B1 5683 PSMA2 27090 ST6GALNAC4 
363 AQP6 5704 PSMC4 27339 PRPF19 
375 ARF1 5912 RAP2B 30837 SOCS7 
468 ATF4 6419 SETMAR 51226 COPZ2 
578 BAK1 6464 SHC1 51617 HMP19 
638 BIK 6480 ST6GAL1 51725 FBXO40 
648 BMI1 6605 SMARCE1 53407 STX18 
660 BMX 6667 SP1 54014 BRWD1 
677 ZFP36L1 7098 TLR3 54788 DNAJB12 
1130 LYST 7157 TP53 54984 PINX1 
1175 AP2S1 7168 TPM1 55215 FANCI 
1211 CLTA 7294 TXK 55300 PI4K2B 
1314 COPA 7415 VCP 55843 ARHGAP15 
2002 ELK1 7903 ST8SIA4 55973 BCAP29 
2070 EYA4 8396 PIP4K2B 56254 RNF20 
2178 FANCE 8702 B4GALT4 56949 XAB2 
2186 BPTF 8835 SOCS2 57192 MCOLN1 
2297 FOXD1 8904 CPNE1 57569 ARHGAP20 
2316 FLNA 9021 SOCS3 58513 EPS15L1 
2624 GATA2 9026 HIP1R 64215 DNAJC1 
2626 GATA4 9230 RAB11B 64326 RFWD2 
3151 HMGN2 9829 DNAJC6 79595 SAP130 
3298 HSF2 10017 BCL2L10 79784 MYH14 
3309 HSPA5 10026 PIGK 79856 SNX22 
3359 HTR3A 10039 PARP3 79874 RABEP2 
3554 IL1R1 10111 RAD50 79982 DNAJB14 
3799 KIF5B 10131 TRAP1 80230 RUFY1 
4000 LMNA 10155 TRIM28 81609 SNX27 
4001 LMNB1 10268 RAMP3 83933 HDAC10 
4084 MXD1 10454 TAB1 84148 KAT8 
4091 SMAD6 10475 TRIM38 85439 STON2 
4144 MAT2A 10524 KAT5 90196 SYS1 
4188 MDFI 10612 TRIM3 92591 ASB16 
4204 MECP2 10791 VAMP5 116988 AGAP3 
4248 MGAT3 10847 SRCAP 135892 TRIM50 
4281 MID1 10947 AP3M2 140460 ASB7 
4335 MNT 11143 KAT7 221002 RASGEF1A 
4478 MSN 22818 COPZ1 221395 GPR116 
4601 MXI1 22820 COPG1 221687 RNF182 
4637 MYL6 22931 RAB18 283383 GPR133 
4758 NEU1 23090 ZNF423 284131 ENDOV 
4928 NUP98 23192 ATG4B 287015 TRIM42 
5002 SLC22A18 23317 DNAJC13 347240 KIF24 
5058 PAK1 23511 NUP188 388552 BLOC1S3 
5296 PIK3R2 25788 RAD54B 440730 TRIM67 
5310 PKD1 25897 RNF19A     
5514 PPP1R10 26118 WSB1     






Figure 3.4: Heat map of the validation results. 
Two repeats of the validation of 147 genes in triplicate are illustrated in this heat map. Each 
colored bar represents a data point. Six bars in the same row illustrate the effects of one siRNA 
pool on BKPyV infection. Non-targeting transfected control is set as 0%, and siTAg control is 










Table 3.3: Results from the validation. Percentage of inhibition of each siRNA pool is listed. 
DNAJB14 103.67 SETMAR 69.31 KAT8 54.17 
DNAJC3 101.61 FBXO6 68.96 ZNF423 53.16 
XAB2 97.15 LMNA 68.33 TRIM38 52.55 
RAB18 96.77 FLNA 68.30 SOCS2 52.49 
SP1 94.96 MNT 68.07 RASGEF1A 52.40 
DNAJB12 93.72 PARP3 67.74 TRIM50 52.15 
SOCS3 92.50 MDFI 67.60 FANCE 51.31 
SNX22 89.33 AP2B1 66.79 KIF5B 50.97 
ASB16 89.21 RAB11B 66.69 EYA4 50.85 
SAP130 89.02 SMARCE1 66.38 RUFY1 50.81 
HSPA5 88.13 IL1R1 66.25 ENDOV 50.71 
LMNB1 87.23 PKD1 65.88 ZFP36L1 50.66 
SRCAP 85.20 PIGK 65.78 VAMP5 50.41 
COPZ2 84.79 TPM1 65.33 BCAP29 49.91 
FBXO4 84.71 ST6GALNAC4 65.16 GPR133 49.40 
BLOC1S3 82.81 HMGN2 65.09 AP3M2 49.09 
CPNE1 82.40 EPS15L1 64.88 LYST 47.75 
PSMA2 82.34 DNAJC13 64.25 TRAP1 47.63 
DNAJC1 82.02 RAD50 63.74 TXK 46.79 
AP2S1 81.82 COPZ1 63.73 HDAC10 46.40 
BPTF 81.76 GPR116 63.71 FANCI 45.37 
GATA2 81.27 NUP98 63.49 TRIM42 44.65 
RNF20 80.93 GATA4 63.38 BIK 44.31 
ELK1 79.58 SHC1 63.06 RAMP3 44.24 
KAT5 79.53 TLR3 63.00 BMX 44.15 
RABEP2 78.59 MGAT3 62.95 ASB7 44.08 
MXD1 78.37 FOXD1 62.94 BAK1 44.02 
COPG1 78.20 AQP6 62.73 PPP1R10 42.60 
MYH14 77.49 SOCS7 62.62 BMI1 40.72 
VCP 77.35 ST6GAL1 62.35 PAK1 40.68 
ARHGAP20 75.69 PIP4K2B 61.96 RNF182 40.48 
ACTN1 75.67 MECP2 61.88 NEU1 38.21 
NUP188 75.53 B4GALT4 61.82 PRKACB 37.81 
TP53 75.17 MAT2A 61.55 PRPF19 37.24 
PI4K2B 74.32 FBXO40 60.68 TAB1 36.98 
PSMC4 74.29 ARF1 60.26 TRIM28 35.88 
AGAP3 74.23 WSB1 59.42 MXI1 34.96 
PINX1 74.10 KAT7 58.96 AP1B1 30.69 
HMP19 73.70 SYS1 58.78 ARHGAP15 29.60 
DNAJC6 73.25 BCL2L10 58.70 ST8SIA4 28.52 
CLTA 72.83 SNX27 58.40 HSF2 21.99 
MCOLN1 72.53 ATG4B 58.10 MID1 19.37 
KIF24 72.15 SMAD6 58.06 FBXL3 14.37 
BRWD1 72.05 MSN 57.44 TRIM67 13.50 
COPA 71.35 SLC22A18 57.31 RFWD2 12.26 
STX18 70.44 TRIM3 57.26 MYL6 10.04 
STON2 69.88 PIK3R2 56.97 PRKCI -6.69 
ATF4 69.56 HIP1R 56.64   
RAP2B 69.47 HTR3A 56.37   




As a second validation, RPTE cells were transfected with the indicated siRNA pools in 
12 well plates, and challenged with BKPyV at 2 days post transfection as described above. 
Protein samples were harvested at 2 days post infection and analyzed via Western blotting. The 
membranes were probed with TAg antibody and an internal loading control, GAPDH. The 
Western blotting result of PI4K2B, AP2S1, ASB16, DNAJC3, SOCS3, SOCS7, TP53, RAB18, 
TLR3, BLOC1S3, VAMP5, VCP, and STON2 were consistent with TAg fluorescent intensity 
analysis (Table 3.3, Figure 3.5A, 3.5B). In addition, Western blotting results suggest that genes 
with an inhibitory value of 65 or higher in Table 3.3 might be essential for BKPyV infection.  
Eliminating candidate obtained due to off-target effects. 
RNA interference is notorious for its off-target effects 33-36. Although only 25nM siRNA 
was applied in our screen, it is impossible to completely avoid off-target effects. To eliminate 
false positive candidates in our validated hits, individual siRNAs from the pools of the top hits in 
which we were most interested were tested. Because we identified many more hits than we could 
study individually, 12 genes, AP2M1, AP2S1, CLTA, PI4K2B, BLOC1S3, STX18, RAB18, 
SNX22, TLR3, ASB16, SOCS3, and SOCS7 were selected for the individual siRNA validation 
assay. Protein samples were prepared after siRNA knockdown and BKPyV infection, and 
assayed for TAg expression by Western blotting as previously described. Interestingly, the 
majority of the individual siRNAs did not inhibit BKPyV infection in the same manner they did 
as pools (Figure 3.6A and Figure 3.6B). All of the four individual siRNAs in the AP2M1 pool 
reduced AP2M1 expression; however, only two of the individual siRNAs inhibited BKPyV 





Figure 3.5A: Screen hit validation via Western blot. 
RPTE cells were transfected with the indicated siRNA pools, infected by BKPyV, and viral 







Figure 3.5B: Screen hit validation via Western blot. (continued). 
RPTE cells were transfected with the indicated siRNA pools, infected by BKPyV, and viral 





Figure 3.6A: Individual siRNA testing to eliminate false positives. 
RPTE cells were transfected with the indicated siRNAs and then infected with BKPyV. Viral 
infection (TAg), GAPDH expression levels, and knockdown efficiency were examined by 







Figure 3.6B: Individual siRNA testing to eliminate false positive hits (continued). 
RPTE cells were transfected with the indicated siRNAs and then infected with BKPyV. Viral 
infection (TAg), GAPDH expression levels, and knockdown efficiency were examined by 





off-target effect in the siRNA pool, thereby determining the phenotype of the pool. After testing 
all of the individual siRNAs for the 12 genes, there were still two viable candidates left: RAB18 
and STX18. Knocking down RAB18 or STX18 significantly inhibited BKPyV infection in 
RPTE cells. Three to four individual siRNAs, out of four, from each siRNA pool were capable of 
reducing both the targeted protein level and the TAg protein level (Figure 3.6A, 3.6B). 
NRZ complex and BKPyV intracellular trafficking. 
RAB18 and STX18 interact with each other and also the NRZ protein complex (Figure 
3.7), which regulates Golgi to ER trafficking in cells 24,27,29. There are several additional 
members of the RAB18/STX18/NRZ protein complex, including Zwilch, ZW10, RINT1, 
SCFD1, and KNTC127. In order to determine if these members of the complex were also 
involved in BKPyV infection, we tested individual siRNAs targeting these proteins. RPTE cells 
were transfected and infected, and protein samples were prepared as previously described. 
Compared to the non-targeting siRNA control, knockdown of ZW10 and RINT1 also 
significantly inhibited BKPyV infection (Figure 3.8). All of these data suggest that the NRZ 
complex plays a role during virus intracellular trafficking. 
Discussion 
BK polyomavirus (BKPyV) was initially isolated more than 40 years ago 1, however, 
understanding the BKPyV life cycle remains a huge challenge. Due to the small size of almost 
all viruses, most available biological tools have certain limitations when applied to viral 
research. Under the electron microscope, internalized BKPyV particles are commonly observed 
to be individually packaged in tight fitting vesicles 13,37. Considering the diameter of BKPyV, 





Figure 3.7: A schematic view of the Rab18, STX18, and NRZ complex with a vesicle containing 








Figure 3.8: The effects of knocking down members of NRZ complex on BKPyV infection. 
 RPTE cells were transfected with the indicated siRNAs, and viral infection (TAg) and GAPDH 





appears to take advantage of multiple endocytic pathways to enter host cell. More importantly, 
some of the endocytic pathways that BKPyV uses are non-productive 10, which suggests that 
morphological observations, especially protein localization evidence, may be deceiving. As 
previously discussed in chapter 2, SV40, BKPyV, murine polyomavirus (MPyV), and cholera 
toxin have been considered to enter the cell via a caveolin-mediated pathway 12,38-42. However, 
subsequent experiments including our results presented in Chapter 2 have demonstrated that 
caveolin is actually completely dispensable 13-15,43-45. Because of the limitations of the existing 
biological tools, research of the earliest stages of the polyomavirus life cycle has progressed 
slowly in the last 40 years. Many questions remain to be answered. 
Whole genome siRNA screening provides us a tool to study the remaining questions. 
However, one of the major challenges of developing an siRNA screen assay is finding a readout 
that is sensitive, cost efficient, and also suitable for high throughput automation. One of the most 
common readouts for a viral siRNA screen is cell viability, however, BKPyV does not lyse host 
cells within a reasonable period of time compared to the duration of the RNAi effect in cells. 
Another common strategy to evaluate viral infection is by incorporating reporter genes into the 
viral genome. Because BKPyV is highly sensitive to genomic modification, several approaches 
attempting to incorporate reporter genes into the BKPyV genome have failed. Moreover, our 
unpublished data indicate that pseudovirus particles containing modified genomes traffic 
differently in host cells compared to wild type virus (Bennett and Imperiale, unpublished data). 
Therefore, constructing a pseudovirus containing a reporter gene was not a viable method for us. 
In addition, immunofluorescent staining for viral protein expression is neither cost- nor time-
efficient for a whole genome screen. For all of these reasons, we needed a novel readout for 




BKPyV does not encode a DNA polymerase in its genome, thus the host DNA replication 
machinery is indispensable for viral replication. In order to fully activate the DNA replication 
machinery, BKPyV subverts cell cycle control and induces G2/M arrest 9. Cells in the G2/M 
phase have at least two times more DNA content compared to G0/G1 cells; thus, they can be 
easily differentiated from non-G2/M cells by DNA staining. Most uninfected RPTE cells in cell 
culture remain in the G0/G1 phase. Because BKPyV infection dramatically increases the 
percentage of G2/M cells, the change in the DNA content can be easily detected and quantified, 
this provided us with a cost-efficient approach to evaluate viral infection in siRNA transfected 
cells. Based on this idea, we developed and used a screening assay that evaluates viral infectivity 
by measuring the percentage of cells in G2/M phase. 
Our primary screen results showed that knocking down 70% of the human genes in RPTE 
cells, inhibited BKPyV infection when compared to the non-targeting control. A similar data 
distribution was also observed in an siRNA screen for HPV infection using the same siRNA 
library 21. All of the siRNA data in our screen formed a normal distribution centered at around 
~35% inhibition compared to the non-targeting control and the siTAg control. Ideally, it is 
expected that most genes would not impact the BKPyV life cycle, and the normal distribution 
should be centered at 0. There are several reasons why the distribution is not centered at 0. One 
reason is that the siTAg transfected cells, the positive control, were not completely immune to 
BKPyV infection. If a mock infected control was used to calculate the inhibitory effect, then the 
average inhibitory effect of the whole screen would have been lower, the normal distribution 
would have been narrower, and the average inhibitory effect would have been closer to zero. 
Another reason is that knocking down a functional protein inside of a live cell will impact the 




replication and shifts the normal distribution to the right. A more important reason is that the 
non-targeting siRNA, the negative control, reproducibly increased BKPyV infection in RPTE 
cells (discussed below). Although the normal distribution is not centered at 0, the final ranking of 
genes in the primary screen is what is most important for the analysis.  
The increased BKPyV infection induced by non-targeting siRNA control could be an off-
target effect of RNAi. Dharmacon reported that another non-targeting pool reduces EGFR 
mRNA expression by more than 50% in an assay- and cell line-dependent manner, which 
indicates that a non-targeting siRNA pool also has off-target effects. In fact, each siRNA in the 
siGENOME library carries a complimentary strand (passenger strand) to enhance the stability of 
siRNA molecules, and the siGENOME siRNA passenger strand is not chemically modified to 
prevent it from incorporating into the RNA-induced silencing complex (RISC); therefore, 
passenger strand integration into RISC possibly increases off-target effects. More importantly, 
even if only the correct guide strand enters the RISC complex, RISC only uses the 2nd to the 8th 
nucleotides of the guide strand, called the seed region, to recognize targeted mRNAs 33-36,46. 
Considering this characteristic of RNAi, the seven-nucleotide seed region can only have 
47=16,384 possible combinations, which is even fewer than the number of total human genes 
(around 20,000~25,000 according to the current estimation). As a result, it appears that off-target 
effects of RNAi are inevitable for whole genome siRNA screens, and a true ‘non-targeting’ 
siRNA pool does not exist 36. This is one of the major limitations of an siRNA screen, and off-
target effects can dramatically increase the expense of validation and lower the efficiency of 
screening. 
There are two common strategies to minimize off-target effects of RNAi. The first 




targeting the same gene, the off-target effect of each siRNA is reduced 75%; meanwhile, the 
effective siRNA concentration for the targeted protein stays the same. This strategy has been 
applied to our primary screen. Another strategy to further minimize off-target effects is to reduce 
the total concentration of siRNA. In fact, we reduced the siRNA concentration to the minimum 
concentration that could be handled by the automated system for the primary screen. After 
applying both strategies to our siRNA screen on BKPyV, we still could not completely avoid off-
target effects. 
We arbitrarily tested knockdown of several genes that we thought were relevant to 
BKPyV infection, such as endocytosis or innate immunity, using TAg expression (assayed by 
Western blotting) for the readout (Figure 3.5A and 3.5B). About half of the genes tested were 
validated in this assay. Extrapolating from this, it is estimated that roughly half of the total 
primary hits could be validated with Western blot. I speculate that knocking down 300-400 genes 
from our primary top hits would also significantly inhibit BKPyV infection when assayed by 
Western blot. However, further validating the effect of each individual siRNA on BKPyV 
infection revealed that individual siRNAs did not always behave in the same way as pooled 
siRNAs. In fact, one siRNA (or more) with a strong off-target effect can determine the overall 
effect of an entire siRNA pool. False positive hits induced by off-target effect are common in 
siRNA screens, and this issue has previously been discussed 35,46-48. In an analysis from 
Franceschini et al., two siRNA screens on the same pathogen, in the same cell line, using two 
different siRNA libraries from different vendors, are completely uncorrelated 49. Due to the 
ubiquitous off-target effects, seed region analysis of the current primary screen data with a 
proper bioinformatics algorithm may be necessary to reveal more true hits in the future 49,50. 




the accurate inhibitory effect of each seed region sequence, which indicates that the siRNA 
screening would be more powerful if the primary screen were done with individual siRNAs. 
This, however, is not practical due to its high expense. Moreover, it suggests that the current 
whole genome siRNA library design in general could be updated. Designing the siRNA library 
based on seed regions would greatly benefit the process of identifying host factors and simplify 
future bioinformatics analysis. 
After validation, Rab18, STX18, ZW10, and RINT1 were identified as essential host 
factors for BKPyV infection. Rab18 protein usually localizes to several cellular compartments, 
such as the ER, the Golgi apparatus, lipid droplets, and the endosome26. Rab18 can interact and 
form protein complex with STX18, ZW10, and RINT1 proteins in cells (Figure 3.7) 27. ZW10 
and RINT1 interact each other with their N termini and form an NRZ protein complex with an 
additional protein, NAG. The NRZ complex indirectly interacts with the t-SNARE protein 
STX18 on the ER membrane 28,29,51. Rab18 is a Ras-like GTPase, and its interaction with the 
NRZ complex is GTP-dependent 24,25,27. STX18 and the NRZ complex form a protrusion about 
20 nm in length from the surface of the ER membrane 52, and this complex is expected to tether 
activated Rab18 on the coat protein I (COPI) vesicle surface and to mediate vesicle fusion with 
the ER membrane. A model of the Rab18/STX18/NRZ protein complex assisting BKPyV 
trafficking is proposed (Figure 3.9) 26. Rab18 on the membrane of the Golgi apparatus or the 
endosome buds and traffics together with virus containing vesicles (Figure 3.9A). The NRZ 
complex on the ER membrane captures vesicles by binding to Rab18-GTP on the vesicle 
membrane (Figure 3.9B). STX18 further interacts with v-SNARE on the vesicles (Figure 3.9C), 






Figure 3.9: A schematic view of BKPyV vesicular trafficking. 
(A) BKPyV forms vesicle on membrane of the Golgi apparatus or the endosome. (B) The GTP 
binding Rab18 interacts with ZW10 of the NRZ tethering complex. (C) STX18 on the ER 





steps, BKPyV successfully enters the ER. Our finding supports the speculation that Golgi to ER 
trafficking may play a role in BKPyV infection. 
Materials and Methods 
Cell culture. Primary renal proximal tubule epithelial (RPTE) cells purchased from 
Lonza were maintained in the medium recommended, REGM BulletKit (REGM/REBM, Lonza, 
CC-3190), at 37˚C with 5% CO2 in a humidified incubator. Cells recovered from the frozen vial 
directly from Lonza (Passage 2) were cultured and expanded for 3 passages. Afterwards, 
expended cells (Passage 5) were passaged one more time and plated for the screening, or 
aliquoted and frozen in liquid nitrogen for later experiments. For all experiments besides screens, 
frozen aliquots (Passage 5) were recovered about one week prior to each experiment, and cells 
were then plated for experiments. 
 
siRNA and siRNA library. The whole-genome human siGENOME smart pool siRNA 
library from Dharmacon was acquired and prepared by the Center for Chemical Genomics 
(University of Michigan). All other siGENOME siRNAs were also purchased from Dharmacon: 
Non-targeting control (D-001206-14); siRNA targeting large T antigen (custom synthesized with 
the sequence 5’ AUCUGAGACUUGGGAAGAGCAU 3’), which corresponds to the natural 
BKPyV 5p miRNA 30.  
 
Primary siRNA screening in 384 well plates. BKPyV (Dunlop) was cultured, purified 
with a cesium chloride linear gradient, and titered as described previously 53,54. The siRNA 




the Basic siRNA Resuspension protocol from Dharmacon. 1 µl 500nM siRNA suspension was 
spotted into each well of 384-well PE viewplates on Biomek laboratory automation workstation. 
RPTE cells were transfected according to the Lipofectamine RNAiMAX (Thermo Fisher 
Scientific) manual. Briefly, transfection complexes were prepared by adding 9 µl of diluted 
transfection reagent (0.78% RNAiMAX reagent v/v in REBM/REGM without antibiotics) to 
each well of 384-well plates with siRNA spotted. The transfection complexes were incubated at 
room temperature for 20 min before adding 1,800 cells suspended in 10 µl REBM/REGM 
without antibiotics to each well. Transfected cells were cultured at 37˚C for 48 h. After the 48 
hours culture, cells were infected with following procedures: incubate plates at 4˚C for 15 min; 
dilute purified BKPyV Dunlop in cold REGM/REBM; dispense 5 µl 1,800,000 IU/ml virus to 
each well with Multidrop Combi reagent dispenser (Thermo Fisher); incubate plates at 4˚C for 1 
hour; transfer plates to 37˚C for additional 48 hours culture. Next, cells were fixed with 4% 
paraformaldehyde (Electron Microscopy Sciences) at room temperature for 20 min, 
permeabilized with 0.1% triton x-100 in PBS for 5 min at room temperature, and stained with 2 
µg/ml Hoechst 33342 (Thermo Fisher, H3570) in PBS for 15 min at room temperature. Cells 
were washed for 3 times with PBS after each staining step. Images of wells were taken with 
ImageXpress Micro XLS high-throughput microscope and analyzed with MetaXpress High-
Content Image Acquisition and Analysis software. The quantified data generated from 
MetaXpress were upload and further analyzed with MScreen, a high-throughput analysis system 
developed by the Center for Chemical Genomics (University of Michigan). 
 
Validation in 96 well plates. BKPyV (Dunlop) was cultured, purified with a cesium 




rehydrated at 500 nM in siRNA buffer (Dharmacon, B-002000-UB-100), according to the Basic 
siRNA Resuspension protocol from Dharmacon. 3 µl 500 nM siRNA suspension was spotted 
into each well of 96-well PE viewplates on Biomek laboratory automation workstation. 
Transfection complexes were prepared by adding 27 µl of diluted transfection reagent (0.78% 
RNAiMAX reagent v/v in REBM/REGM without antibiotics) in each well of a 96-well plates 
with siRNA spotted. The transfection complexes were incubated at room temperature for 20 min 
before adding 5,400 cells suspended in 30 µl REBM/REGM without antibiotics to each well. 
Transfected cells were cultured at 37˚C for 48 h. After the 48 hours culture, cells were infected 
with following procedures: incubate plates at 4˚C for 15 min; dilute purified BKPyV Dunlop in 
cold REGM/REBM; dispense 15 µl 1,800,000 IU/ml virus to each well with Multidrop Combi 
reagent dispenser (Thermo Fisher); incubate plates at 4˚C for 1 hour; transfer plates to 37˚C for 
additional 48 hours culture. Next, cells were fixed with 4% paraformaldehyde (Electron 
Microscopy Sciences) at room temperature for 20 min; permeabilized with 0.1% triton x-100 in 
PBS for 5 min at room temperature. The cells were then blocked with 5% goat serum in PBS at 
room temperature for 1 hour and probed with with TAg antibody 55 at a 1:150 dilution and 1:200 
FITC labeled goat anti-mouse IgG antibody (Sigma) successively for 1 hour each at room 
temperature. All antibodies were diluted in 5% goat serum. At last, nuclei were visualized with 2 
µg/ml Hoechst 33342 (Thermo Fisher, H3570) in PBS for 15 min at room temperature. Cells 
were washed for 3 times with PBS after each staining step. Images of wells were taken with 
ImageXpress Micro XLS high-throughput microscope and analyzed with MetaXpress High-
Content Image Acquisition and Analysis software. The averages of integrated FITC fluorescence 





Secondary validation in 12 well plates. siRNAs were rehydrated at 1 µM in siRNA 
buffer (Dharmacon, B-002000-UB-100). Transfection complexes were prepared by mixing 20 µl 
of 1 µM siRNA with 380 µl of diluted transfection reagent (0.74% RNAiMAX reagent v/v in 
REBM/REGM without antibiotics) in each well of 12-well plates. The transfection complexes 
were incubated at room temperature for 20 min before adding 70,000 cells suspended in 400 µl 
REBM/REGM without antibiotics to each well. RPTE cells were infected as follows at 2 days 
post transfection. Cells were pre-chilled for 15 min at 4˚C. Purified viruses were diluted to 
87,500 IU/ml (MOI 0.5) in REBM/REGM. 400 µl of the diluted virus were added to the wells 
and incubated at 4˚C for 1 hour with shaking every 15 minutes to distribute the inoculum over 
the entire well. The plate was transferred to 37˚C after the 1 hour incubation. 
 
Preparation of protein lysates. Cells were lysed at 48 hours post infection with E1A 
buffer (50 mM HEPES [pH 7], 250 mM NaCl, and 0.1% NP-40, with inhibitors: 5 µg/ml PMSF, 
5 µg/ml aprotinin, 5 µg/ml leupeptin, 50 mM sodium fluoride and 0.2 mM sodium orthovanadate 
added right before use). Protein concentration was quantified with the Bradford assay (Bio-Rad). 
 
Western blotting. Protein samples were separated on 12% SDS-PAGE gels. After 
electrophoresis, the proteins were transferred to a nitrocellulose membrane (pore size 0.2 µm) 
with a Bio-Rad Trans-Blot Cell in Towbin transfer buffer (25 mM Tris, 192 mM glycine, 20% 
methanol) at 60 V overnight. Membranes were blocked with 2% nonfat milk in PBS-T buffer 
(144 mg/L KH2PO4, 9 g/L NaCl, 795 mg/L Na2HPO4, pH 7.4, 0.1% Tween 20) for 1 hour. 
Membranes were probed with primary and secondary antibodies diluted in 2% milk in PBS-T as 




(Sigma SAB4200173) at 1:10,000, AP2M1 (Abcam ab75995) at 1:10,000; GAPDH (Abcam 
ab9484) at 1: 10,000; horseradish peroxidase (HRP)-conjugated ECL sheep anti-mouse (GE 
healthcare NA931V) at 1: 5,000; and HRP-conjugated ECL donkey anti-rabbit antibody (GE 
healthcare NA934V) at 1: 5,000. Protein bands were further visualized with HRP substrate 
(Millipore, WBLUF0100) and exposure to x-ray film. 
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Although polyomaviruses are genetically similar, it has been reported that 
polyomaviruses use different pathways to infect host cells. Conflicting reports have been 
published on the endocytic process of SV40 and murine polyomavirus (MPyV). In order to 
investigate BKPyV infection in greater detail, caveolin 1, caveolin 2, and clathrin heavy chain 
were silenced by transfecting RPTE cells with siRNA pools; however, BKPyV infection was not 
affected. My results provided in this dissertation (Chapter 2, ref 1) together with other reports 
demonstrate that caveolin is dispensable for SV40, MPyV, and BKPyV infection 1-6. In addition, 
by silencing UDP-glucose ceramide glucosyltransferase (UGCG) and performing a ganglioside 
rescue assay, we confirmed functionally that BKPyV infection requires ganglioside receptors. In 
order to identify the host factors associated with a BKPyV infection, we developed and 
performed an automated whole genome siRNA screen for factors important for BKPyV infection 
in primary human renal proximal tubule epithelial (RPTE) cells. We used the percentage of cells 
arrested in G2/M phase as a readout. After validation, we showed that RAB18 and STX18 along 




Whole genome siRNA screening 
Since siRNA was introduced as a biological tool, it has been extensively applied to 
research on viruses, and thousands of host factors required for infection have been identified for 
various viruses, directly or indirectly. Each siRNA screen performed on HIV identified hundreds 
of host factors distributed into various pathways 7-9. In a hepatitis C virus (HCV) screen, 
PI4KIIIα was identified to interact with the nonstructural protein 5A, and PI4KIIIα is important 
to form viral replication complexes 10. Moreover, using an siRNA screen, SON DNA binding 
protein was identified as a critical protein regulating influenza virion trafficking to the late 
endosomes 11. Vacuolar ATPase and calcium/calmodulin-dependent protein kinase IIb were also 
identified as essential host factors for influenza virus in a separate siRNA screen 12. In addition, 
the ubiquitin ligase CBLL1 was found to be important for West Nile virus (WNV) 
internalization, thereby revealing the role of the endoplasmic reticulum associated protein 
degradation (ERAD) pathway in WNV infection 13. The role of the Golgi apparatus in human 
papillomavirus (HPV) lifecycle had been a mystery until an siRNA screen performed on HPV 
revealed that the retromer and endosome-to-Golgi apparatus trafficking is essential to HPV 
infection 14,15. An siRNA screen performed on another polyomavirus, SV40, showed that DNAJ 
proteins are important for SV40 to exit the ER 16,17. All these host factors would have been 
difficult to identify by educated guesses, and these host factors listed are only a fraction of host 
factors identified with the help of siRNA screen. 
However, the siRNA screen has its own limitations. When siRNA was first introduced, 
RNAi was believed to be highly specific 18. However, subsequent studies demonstrate that the 
specificity of RNAi is much lower than originally speculated. Each siRNA screen on HIV 




which suggests that off-target effects could be responsible for some of the non-overlapping hits. 
The RNA-induced silencing complex (RISC) only uses the 2nd to the 8th nucleotides of the guide 
strand, called the seed region, to recognize targeted mRNAs 22-26. Considering this characteristic 
of RNAi, the seven nucleotide seed region can have 47=16,384 possible combinations. Moreover, 
there are only 10,868 total seed regions in total in the whole genome siRNA library that we used 
for our primary screen. This number is about half the total number of human genes (around 
20,000~25,000 according to the current estimation). As a result, off-target effects of RNAi are 
inevitable for a whole genome siRNA screen, and it is estimated that hundreds of genes would be 
affected by any siRNA pool, including the non-targeting siRNA control 23. During the validation, 
I found that one siRNA with a strong off-target effect in many of the pools could eventually 
determine the phenotype of the pool. This is one of the major limitations of an siRNA screen. 
Sorting out off-target effects can dramatically increase the expense of validation and lower the 
yield of screening. 
Bioinformatics analysis is a useful way to eliminate some false positives. Analyzing 
screening data based on individual seed region sequences instead of siRNA pools can 
dramatically increase the correlation between siRNA screens on the same pathogen, thereby 
increase validation efficiency 27,28. However, because siRNA pools were used for our primary 
siRNA screen on BKPyV, and up to four seed region sequences were mixed in the same siRNA 
pool, the accurate inhibitory effect of each seed region sequence could not be calculated, which 
would partially compromise the accuracy of the seed region analysis. This indicates that applying 
individual siRNAs to the primary screen could dramatically simplify the bioinformatics analysis 




on seed regions and performing bioinformatics analysis afterward may enhance the accuracy and 
efficiency of future screens. This approach also results in added expenses, however. 
BKPyV receptor and attachment 
BKPyV attachment to the host cell is the most well studied early step of BKPyV 
infection. Subsequent to the finding that gangliosides GD1b and GT1b are BKPyV receptors 29, 
structures of the BKPyV capsid and the capsid protein-receptor complex have also been carefully 
studied based on crystal structures of other polyomaviruses 30-36. In the case of BKPyV, GD1b 
and GT1b bind to the shallow grooves on the surface of VP1, and each VP1 pentamer is capable 
of interacting with five ganglioside molecules 31. Gangliosides are commonly enriched in 
cholesterol-rich regions of the plasma membrane referred to as lipid rafts. Cholesterol assists the 
positioning of gangliosides so that the oligosaccharide chains are pointing in the correct direction 
for the initial attachment 37,38. 
Co-receptors for polyomavirus are mostly unknown. JC polyomavirus uses serotonin 
receptors to infect cells 39, and integrin mediates endocytosis of murine polyomavirus (MPyV) 
after attachment 40. After initial attachment, BKPyV may also use protein co-receptors to 
coordinate the entry process. Dugan et al. reported that cleaving oligosaccharide chains on the 
cell membrane with neuraminidase blocks BKPyV virus entry, and restoring N-linked 
glycoproteins with α(2,3)-(N)-sialyltransferase rescues BKPyV infection 41, which suggests that 
a N-linked glycoprotein may serve as BKPyV co-receptor. Because BKPyV interacts with its 
receptors, gangliosides GT1b and GD1b, via the α2,8-linked N-acetylneuraminic acid (sialic 
acid) on those two gangliosides 31, and because α2,3-linked sialic acid alone cannot reach the 




infection, it must interact with the capsid protein VP1 using a different domain than the 
ganglioside binding domain. On the other hand, digestion of membrane proteins with proteinase 
K enhanced MPyV infection 42, which suggests that glycoproteins on the plasma membrane 
serve as traps for polyomavirus. Another study from Benjamin et al. supports the same idea, that 
eliminating gangliosides alone is sufficient to fully block MPyV infection, and polyomavirus 
particles all enter non-productive pathways when gangliosides are not used as a receptor 43. In 
my opinion, all of the evidence point to the same idea that gangliosides instead of membrane 
proteins are required for polyomavirus entry. In other words, protein co-receptors may not be 
required or even exist for polyomaviruses. 
BKPyV Endocytosis 
The process of BKPyV endocytosis has been extensively investigated. The current model 
indicates that BKPyV enters the caveolae endocytic pathway after initial attachment to receptors 
GD1b/GT1b and eventually enters the host cells in tight-fitting vesicles 44,45. In Vero cells, 
depleting the membrane cholesterol with methyl-β-cyclodextrin (MβCD) blocked cholera toxin 
endocytosis as well as BKPyV infection 46,47 . In addition, overexpressing mutant caveolin 1 or 
inhibiting tyrosine kinases with genistein blocked viral infection. Genistein is well known for its 
effect as a tyrosine kinase inhibitor, and it is also considered as an inhibitor of the caveolin-
mediated pathway 46. However, genistein regulates too many pathways to draw any conclusions 
about its effect on BKPyV endocytosis 48,49. In RPTE cells, one group reported that interfering 
with cholesterol function with both MβCD and nystatin or knocking down caveolin 1 inhibited 




caveolin protein in both Vero and RPTE cells immediately after endocytosis, which led to their 
conclusion that caveolae plays a role in BKPyV entry. 
 There are several strategies that can be used to interfere with cholesterol function, and 
most of these strategies have limitations 50. In vitro, MβCD directly extracts cholesterol from the 
plasma membrane and releases cholesterol to the culture media 50. Because caveolin 1 directly 
interacts with cholesterol, caveolae cannot form under MβCD treatment 51. However, MβCD 
treatment not only releases cholesterol from the plasma membrane but also releases gangliosides 
and other transmembrane proteins 50. Therefore, the inhibitory effect is more likely to be the 
result of losing BKPyV receptors rather than caveolae. Moreover, nystatin binds to and forms a 
complex with cholesterol on the cell membrane 52, which can be toxic to the cells. Nystatin is 
insoluble in aqueous solutions, however, Sigma still recommends a 50 mg/ml stock suspension 
in water because nystatin is effective in a suspension. After treatment, we easily observed 
nystatin crystal precipitation in our experiments; therefore, it is surprising that nystatin would 
cause a dose-dependent effect in RPTE cells 47. According to the solubility information listed on 
the Sigma website, nystatin is soluble in DMSO at 5 mg/ml. If DMSO were used as a vehicle for 
nystatin delivery, then 100 µg/ml of nystatin means addition of 2% of DMSO to the cell culture 
media, which is toxic to cells. I made an attempt to reproduce the reported inhibitory effect of 
nystatin on BKPyV in RPTE cells 47. However, I could not reproduce the published result: 
nystatin did not impact BKPyV infection in my experiments (Figure 2.3A). In any case, 
cholesterol is important for many biological activities including clathrin-mediated endocytosis 53; 





Overexpressing mutant caveolin-1 has multiple effects on cells in addition to reducing 
caveolin activity. When viewed under the microscope, the overexpressed mutant caveolin 1 
accumulated in the perinuclear region 46,54. This accumulation may completely block the exit of 
the virus from the Golgi apparatus or other trafficking pathways 55. Therefore, the fact that 
mutant caveolin 1 blocked infection does not necessarily mean that caveolin is important for 
BKPyV entry. In addition, my siRNA knockdown experiments showed that caveolin 1 is 
dispensable for BKPyV infection; thus the inhibitory effect of mutant caveolin 1 is more likely to 
be a side effect. 
Because gangliosides are enriched in lipid rafts containing abundant cholesterol 56, and 
because caveolin as a cholesterol interacting protein also accumulates in lipid rafts, caveolin and 
gangliosides must colocalize on the plasma membrane. Because gangliosides serve as receptors 
for BKPyV, BKPyV must colocalize with caveolin at early stages of the virus-host cell 
interaction. Additionally, polyomavirus enter cells via multiple pathways including non-
productive pathways; therefore, colocalization results cannot be used to prove that caveolae are 
required for BKPyV infection. 
All of the experiments described above indirectly tested the function of caveolin 1 on 
BKPyV infection. Moriyama et al. also reported that knocking down caveolin 1 inhibited 
BKPyV infection 47. In their experiment, RPTE cells were transfected with concentrated siRNA 
pool targeting caveolin 1 (100nM), which may enhance off-target effects. Transfected cells were 
infected with BKPyV at 48 hours post transfection and protein samples were harvested at 5 days 
post infection. At 5 days post infection, BKPyV would have already undergone two infection 
cycles. An over 80% reduction of TAg expression was observed when there was a 50% 




protocol exactly. In addition, I achieved significantly more than 50% caveolin 1 knockdown with 
my optimized protocol, yet I observed no TAg expression reduction. This suggests that the 
caveolin 1 protein is dispensable for BKPyV infection in RPTE cells. Caveolin proteins have 
long been considered to mediate SV40, MPyV, and BKPyV infection; however, subsequent 
experiments showed that SV40, MPyV, and even cholera toxin can invade caveolin-deficient 
cells. My results are consistent with these later observations 1-6. The major capsid protein VP1 of 
MPyV, SV40, Merkel cell polyomavirus, and JC polyomavirus are well conserved except for the 
ganglioside interacting domain 31,57. It makes the most sense that although polyomaviruses bind 
to different gangliosides, they may follow the same endocytic pathway when entering host cells. 
Results described in Chapter 2 demonstrate that gangliosides are essential for BKPyV 
infection, and that caveolin and clathrin are both dispensable for BKPyV entry. Knocking down 
caveolin 1, caveolin 2, and clathrin heavy chain did not affect BKPyV infection. Partial 
disassembly of the actin filaments with cytochalasin D increased virus infection when used at a 
low concentration. All of the above findings suggest that BKPyV may infect host cells via a 
novel endocytic pathway. 
Many in vitro plasma membrane models have been developed and widely applied to the 
study of endocytosis. One of the model systems is giant unilamellar vesicles (GUVs) 58,59, which 
have been used to study the attachment and endocytic processes of toxins and viruses. Because 
GUV is an artificial, protein-free system, the impact of protein can be eliminated and the 
composition of the membrane can be easily manipulated. It has been reported that cholera toxin, 
a toxin that binds ganglioside GM1, alone can induce phase separation in GUVs. In addition, 
cholera toxin can induce the formation of budding vesicles from GUVs, and cholesterol plays a 




SV40 and GUVs showed that SV40 is capable of inducing deep invaginations without the help 
of any host proteins or cholesterol 61. In the process of invagination formation, the length of 
ceramide tails of the ganglioside is important 61, suggesting that the binding force between 
gangliosides and capsid proteins is responsible for formation of the deep invagination. 
Morphologically, this deep invagination would look like a single polyomavirus encapsulated in a 
tight-fitting vesicle if a cross section of the invagination were observed under the EM 2,44. 
Moreover, a single viral particle may be sufficient to induce an invagination, as previously 
observed under EM during SV40 entry 2. 
In summary, I propose that cholesterol in the plasma membrane regulates the position of 
the gangliosides and facilitates initial attachment (Figure 4.1) 38. After the initial attachment to 
the gangliosides on the cell membrane, the BKPyV capsid recruits more gangliosides to the 
attachment site. By recruiting more gangliosides, the interaction between VP1 and gangliosides 
with long ceramide tails forms invaginations on the cell membrane, and no host proteins are 
required for this process. Cholesterol is not required for formation of this invagination 61. 
However, cholesterol regulates budding in GUVs and in retrograde trafficking 60,66, and 
cholesterol interacts with ceramide tails, which will stabilize the entire deep invagination 
structure and may benefit the final fission step of virus-containing vesicles.  
Lastly, how the virus-containing vesicle pinches off from the invagination is still 
unknown. There are two possible ways. First, it may get pinched off with the help of other host 
proteins in the same way as other vesicles. Dynamin assists vesicle fission in many vesicular 
trafficking pathways 62. Dynasore, a dynamin inhibitor, inhibited BKPyV infection in RPTE cells 
(Figure 2.7A). However, the inhibitory effect of Dynasore was not specific, and it blocked 




needs host protein assistance is still unknown. Alternatively, because each BKPyV virion can 
interact with 360 ganglioside molecules, the fission step may be solely dependent on the 
interaction between gangliosides and capsid proteins, and independent of host proteins. In 
addition, our primary screen showed that knocking down dynamin did not affect G2/M arrest 
induced by BKPyV. The real role of dynamin in BKPyV infection is still unclear and the 
machinery involved in vesicle fission remains to be revealed. 
Endosome to ER retrograde transport 
After endocytosis, there is no direct evidence that shows colocalization of BKPyV with 
the endosome 63, however evidence showing other polyomaviruses entering the endosome is 
abundant 4,54,64. After entering the endosome, BKPyV particles undergo a sorting step in the late 
endosome/lysosome and traffic along with gangliosides 65,66. Acidification of the late endosome 
is essential to activate this sorting machinery 63. NH4Cl blocks the acidification step and 
completely abolishes virus infection. After 2 hours post infection, NH4Cl no longer inhibits viral 
infection, suggesting that all infectious viral particles have moved into a secondary vesicle and 
have already trafficked through the late endosome/lysosome at that time. After passing through 
the endosome, the majority of the details regarding viral trafficking are missing, and only an 
incomplete model with few time points is available. At 4 hours post infection, a few viral 
particles have already reached a destination at which microtubules are important for trafficking; 
meanwhile, it takes the majority of viral particles 10~12 hours to reach this destination 63. 
Because BKPyV trafficking is not synchronized after the endosome step, it is possible that 
BKPyV takes several different routes to reach the ER. At 8 hours post infection, BKPyV capsids 




passed from the endosome when VP1 cleavage products could be detected. I speculate that 
BKPyV capsid does not disassociate from gangliosides or undergo conformation changes in the 
late endosome or lysosome. This speculation is also consistent with subsequent reports that 
gangliosides sort the BKPyV particle to the ER, and capsid conformational changes are not 
required before BKPyV enters the ER 65,66. Vesicles containing BKPyV are proposed to fuse 
with the ER membrane; however, the details of this process are still unclear. BKPyV particles 
are expected to disassemble in the ER with the help of several ER proteins including protein 
disulfide isomerases 63,67-70.  
Gangliosides have been reported to assist the sorting process and regulate endosome to 
ER trafficking 65. In addition, the ceramide structure is a determinant of sorting and the transport 
destination 61,66. Because oligosaccharide chains of gangliosides interact with VP1 and are buried 
in the shallow groove of VP1, the only part of the gangliosides that the cell can use to identify, 
categorize, and sort are the ceramide tails. Because polyomaviruses use the gangliosides for 
receptors, I speculate that although different polyomaviruses bind to different gangliosides to 
enter the cell, they fall into the same ganglioside-dependent retrograde transport pathway, which 
transports the virus to the ER with the help of Rab proteins. After acidification and maturation of 
the endosome, the late endosome/lysosome sorts the gangliosides into different secondary 
vesicles that traffic to different cell compartments based on the ceramide structure 66. Because 
BKPyV associates with gangliosides 65, BKPyV particles should traffic to different 
compartments along with the gangliosides. In addition, gangliosides that do not traffic to the ER 
may also serve as a trap for BKPyV in addition to glycoproteins on the plasma membrane 42. It 
also has been found that cholera toxin binding to gangliosides is dispensable for ganglioside 




intrinsic and is independent of toxin or virus binding. In other words, BKPyV may act as a 
“hitchhiker” during the retrotranslocation of gangliosides to the ER; therefore, a protein co-
receptor may not be required for polyomavirus infection 66. Lastly, it is proposed that 
gangliosides traffic to the ER via several routes 66, which may explain why BKPyV trafficking in 
RPTE cells is not synchronized after BKPyV passes through the endosome. The fast trafficking 
viral particles may traffic directly from the late endosome to the ER; in contrast, the slow 
trafficking particles may traffic to the Golgi apparatus before trafficking to the ER.  
Two more questions regarding the process of BKPyV trafficking from the endosome to 
the ER are whether or not BKPyV traffics through the Golgi apparatus at all, and whether or not 
trafficking through the Golgi apparatus is necessary for successful infection. Few studies have 
been performed attempting to address this question 71. Most of the reports claim that viral 
intracellular traffic bypasses the Golgi apparatus; however, some the reports support the idea that 
BKPyV traffics to Golgi apparatus. First, brefeldin A, an inhibitor that blocks coat protein I 
(COPI) vesicle formation on the Golgi apparatus 72, inhibits BKPyV infection 63,73. Second, 
cholera toxin, shiga toxin, HPV, and BKPyV undergo retrograde transport to the ER, and this 
retrograde transportation can be blocked with the chemicals retro-1 and retro-2 74,75, suggesting 
that they share similar trafficking pathways. Cholera toxin, shiga toxin, and HPV have been 
demonstrated to visit the Golgi apparatus during intracellular trafficking 14,52,76,77, suggesting that 
BKPyV may also traffic to the Golgi apparatus. Third, there is one report that showed the 
colocalization of BKPyV and the Golgi apparatus 71. Fourth, as previously discussed, 
gangliosides mediate the sorting process of polyomavirus during retrograde traffic and 
gangliosides traffic to the Golgi apparatus 66; therefore BKPyV should follow gangliosides and 




from synchronized 63. After leaving the endosome, there is a more than 4-hour difference 
between the fastest traveling viral particles and the slowest particles, which supports the idea that 
the virus may take several pathways to reach the same destination. Lastly, our primary screen 
result showed that RAB5A, RAB7, RAB9A, RAB11B, and SEC61A are important for BKPyV 
infection, which strongly supports the idea that BKPyV traffics along with gangliosides to the 
Golgi apparatus 66.  
If BKPyV traffics to the Golgi apparatus, then the next question would be whether or not 
trafficking to the Golgi apparatus is required for BKPyV infection. Although BKPyV likely 
travels to the Golgi apparatus, I think that this route is probably not required for infection. 
EHNA, a dynein inhibitor, disrupts normal Golgi apparatus structure but does not affect BKPyV 
infection. Moreover, although cholera toxin traffics to the Golgi apparatus, trafficking to the 
Golgi apparatus is not required for cholera toxin to transport to the ER, and only the trans-Golgi 
network is required 76,78. Finally, a direct retrograde traffic pathway between the endosome and 
the ER may exist 65,66,79; therefore, even if BKPyV traffics to the Golgi apparatus, this process is 
more likely to be dispensable for BKPyV infection. However, I speculate that trafficking 
efficiency may be compromised without the Golgi apparatus route, because the Golgi apparatus 
route appears to be the dominant route during ganglioside retrograde trafficking. 
One remaining question is what machinery is used by BKPyV to penetrate the ER 
membrane and enter the ER lumen. A study from Nelson et al. shows that the capsid 
conformational change and minor protein exposure are not required for BKPyV infection 70. This 
is consistent with my speculation that BKPyV is encapsulated in sorting vesicles and associated 
with gangliosides on its way to the ER. After further validation of our siRNA screen hits, RAB18 




experiments showed that knocking down ZW10 and RINT1 also inhibited viral infection, which 
indicates that RAB18, STX18, and the NRZ complex may play an important role in BKPyV 
infection. 
Rab18 protein interacts with multiple proteins in cells, including RINT1, ZW-10, Zwilch, 
STX18, and ROD 80, which have been found to assist Golgi to ER trafficking 81. The NRZ 
complex structure has also been partially solved (Figure 3.7) 81-83. In brief, the N terminals of 
RINT1 and ZW10 mediate protein-protein interaction, and RINT1 further interacts indirectly 
with proteins on the ER membrane including STX18. The ZW10 interaction with RAB18 is 
GTP-dependent, and RAB18 is thought to assist the tethering of COPI vesicle to NRZ complex 
on the ER membrane 80. The protein-protein interaction studies indicate that ZW10, RINT1, and 
STX18 together form a linear structure, and this complex is predicted to form a protrusion about 
20 nm in length from the ER membrane 84. This, in turn, is expected to interact with Rab18 on 
the vesicle surface and mediate vesicle fusion (Figure 3.9). ZW10 also has additional functions 
besides being part of the NRZ. It also forms a RZZ complex 81, which regulates mitosis and 
chromatin separation. However, because BKPyV induces G2/M arrest, ZW10 is not likely to 
affect BKPyV infection when it is part of the kinetochores.  
Other viruses and toxins 
Gangliosides play important roles in both endocytosis and retrograde trafficking. 
Polyomaviruses and several toxins are proposed to take advantage of lipid-mediated endocytosis, 
which has been reviewed by Ewers and Helenius 85. 
Beside polyomaviruses, some non-enveloped viruses infect cells in a similar manner; 




establish an infection 86. By silencing critical ganglioside synthesis enzymes, gangliosides have 
been demonstrated to be important for rotavirus infection 87. After binding to gangliosides, 
rotavirus also traffics to and gets sorted in the endosome88. Norovirus also binds to gangliosides 
89,90, and forms a deep invagination on GUVs 91. Norovirus may also get internalized and traffic 
to the endosome in the same way as polyomavirus. Some adeno-associated viruses (AAV) use 
gangliosides as receptors, and AAV may also traffic to the Golgi apparatus and the ER before 
entering the cytosol 92. Gangliosides therefore may guide AAV through the sorting process. 
Lastly, HPV infection is also independent of clathrin, caveolin, cholesterol, and dynamin, and the 
retrograde paths of both HPV and BKPyV can be blocked with retrograde traffic inhibitors retro-
1, retro-2, and BFA. This suggests that HPV and BKPyV share the same pathway during 
intracellular trafficking: therefore, HPV may also enter this lipid mediated retrograde trafficking 
pathway. 
Considering that ganglioside to ER trafficking is intrinsic 66, I speculate that viruses or 
toxins that bind to gangliosides may hitch onto gangliosides and traffic along with them to the 
endosome, Golgi apparatus, or ER. Some transmembrane proteins may affect the intrinsic 
ganglioside recycling; therefore, extra care is necessary when interpreting results from the co-
receptor experiments. 
Conclusions 
In this dissertation, details about the process of BKPyV attachment and intracellular entry 
have been discussed. Based on these results, I propose the following model. At the beginning of 
the BKPyV life cycle, the cholesterol in the plasma membrane regulates the position and 




viral attachment (Figure 4.1). After the virus attaches to the gangliosides, the rest of the available 
VP1 capsid proteins will bind to adjacent gangliosides. As more and more gangliosides are 
recruited to the site of attachment, invaginations gradually occur based on the binding force 
between gangliosides and VP1. Because each BKPyV particle is capable of interacting with 360 
ganglioside molecules from any direction, the interaction between gangliosides and VP1 may be 
sufficient for vesicle fission without the help of other host proteins; however, it is still possible 
that host proteins assist the fission step (Figure 4.2A). At this stage of infection, because both 
caveolin and gangliosides are enriched in the cholesterol-rich domain of the plasma membrane, 
BKPyV is expected to colocalize with caveolin, although caveolin is not required for 
invagination formation. After endocytosis (Figure 4.2B), the virus enters the endosome, still 
binds to gangliosides. Late endosome acidification activates sorting machinery mediated by Rab 
proteins that sort gangliosides into COPI-coated secondary vesicles based on the ceramide 
structures of the gangliosides. When gangliosides are sorted in to secondary vesicles, the BKPyV 
particles that bind those gangliosides are also sorted into the secondary vesicles along with the 
gangliosides. After this sorting step, a few BKPyV particles traffics along microtubules towards 
the ER (Figure 4.2E). A majority of the secondary vesicles traffic to the Golgi apparatus before 
trafficking to the ER (Figure 4.2C), and arrive at the ER (Figure 4.2D) about 4-8 hours later than 
vesicles directly trafficking to the ER. When vesicles containing viral particles reach the adjacent 
area of the ER, Rab18 on the surface of the vesicle interact with STX18/NRZ complex, which 
mediates fusion of the virus-containing vesicles to the the ER membrane (Figure 4.2F); thus 
BKPyV reaches the ER lumen (Figure 3.9). 
This dissertation provided new details regarding polyomavirus endocytosis and 





Figure 4.1: Model of BKPyV attachment and endocytosis.  
Cholesterol regulates the position of gangliosides in the membrane. BKPyV particles first bind to 
gangliosides GD1b or GT1b on the cell surface. The BKPyV particle recruits more ganglioside 







Figure 4.2: BKPyV intracellular traffic.  
(A) Vesicle fission. (B) Encapsulated virus. Virus is still binding to gangliosides. (C)(D)(E) 
Virus sorted based on the ceramide structure of ganglioside. After acidification, viral particles 
are encapsulated in secondary vesicle. The secondary vesicles then traffic to ER directly or via 
the Golgi apparatus as determined by ganglioside structure. (F) Secondary vesicles with Rab18 






become internalized via different pathways: the caveolin mediated pathway, the clathrin 
mediated pathway, and the caveolin- and clathrin-independent pathway. However, my 
experiments along with those of others demonstrate that caveolin is dispensable for MPyV, 
SV40, and BKPyV infection. This suggests that polyomaviruses use similar pathways to enter 
host cells. Based on this finding, a new model of viral entry and intracellular trafficking is 
proposed. Many other viruses have similar trafficking patterns compared to polyomavirus, such 
as HPV, norovirus, and rotavirus. These viruses could also take advantage of some parts of this 
pathway to establish infection.  
In the future, several topics regarding viral entry and intracellular trafficking are worth 
further investigation. First, the fission step of BKPyV endocytosis is still unknown. The function 
of the dynamin protein in viral endocytosis could not be determined, either with Dynasore 
treatment, or with the siRNA screen. Dynamin has multiple roles in various cell compartments 
62, therefore more careful studies are necessary to reveal its role in BKPyV infection. Next, the 
viral disassembly process is far from fully understood. As previously discussed, BKPyV remains 
intact before fusing to the ER, and it has been shown that ER proteins are important for capsid 
disassembly. However, how VP1 is cleaved, and whether this cleavage process is necessary for 
BKPyV infection is still a mystery. Third, more evidence is required to fully understand the role 
of the RAB18/STX18/NRZ protein complex. Further study of this complex will also help answer 
the question of the importance of the Golgi apparatus in BKPyV entry. The fourth unsolved 
question is the role of Rab proteins during ganglioside retrograde trafficking. Applying 
retrograde trafficking inhibitors, retro-1 and retro-2, blocked the trafficking of cholera toxin, 
shiga toxin, polyomavirus, and HPV, which suggests that the Rab-dependent ganglioside 




Understanding this pathway will be rewarding, and will also help answer many unsolved 
questions. This may eventually benefit clinical applications, suggesting ways of preventing virus 
spread to other cells after reactivation.  
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